

CITATION REPORT

List of articles citing

Response criteria for phase II studies of supratentorial malignant glioma

DOI: 10.1200/jco.1990.8.7.1277

Journal of Clinical Oncology, 1990, 8, 1277-80.

Source: <https://exaly.com/paper-pdf/21480859/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2169	Oligodendroglioma: a new chemosensitive tumor. <i>Journal of Clinical Oncology</i> , 1990 , 8, 2090-1	2.2	8
2168	Phase II study of tauromustine in malignant glioma. 1992 , 28A, 1959-62		14
2167	Aggressive Oligodendroglioma. 1992 , 31, 78-82		84
2166	Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas. 1992 , 34, 73-6		8
2165	Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). 1992 , 13, 583-8		3
2164	Response of brain metastases from breast cancer to systemic chemotherapy. 1992 , 69, 972-80		204
2163	Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. 1993 , 29A, 940-2		207
2162	The therapeutic challenge of gliomas. 1993 , 29A, 936-9		3
2161	5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. 1993 , 4, 591-5		4
2160	Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 1994 , 12, 2013-21	2.2	384
2159	Brain tumor chemotherapy trials: slow start, but quickly gaining. <i>Journal of Clinical Oncology</i> , 1994 , 12, 2003-4	2.2	1
2158	Recording neurological impairment in clinical trials of glioma. 1994 , 19, 37-49		49
2157	The basis for current treatment recommendations for malignant gliomas. 1994 , 20, 111-20		98
2156	New agents in the treatment of primary brain tumors. 1994 , 20, 141-53		4
2155	Primary central nervous system lymphoma in Japan--a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. 1994 , 19, 197-215		76
2154	The management of histologically unverified presumed cerebral gliomas with radiotherapy. 1994 , 28, 405-13		79
2153	Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. 1994 , 30A, 1809-15		55

2152	Clinical application of the blink reflex with stimulation of the mental nerve in lesions of the inferior alveolar nerve. 1994 , 44, 2356-61		25
2151	Chemioterapia arteriosa nel trattamento dei gliomi maligni. 1994 , 7, 193-195		
2150	Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. 1995 , 37, 17-27; discussion 27-8		92
2149	Recommendations of the Brain Tumor Subcommittee for the reporting of trials. SIOP Brain Tumor Subcommittee. International Society of Pediatric Oncology. 1995 , 24, 104-8		88
2148	A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma. 1995 , 72, 766-8		10
2147	Advances in Chemotherapy for Brain Tumors. 1995 , 13, 795-812		23
2146	Response and control: lessons from oligodendroglioma. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2475-6	2.2	12
2145	Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2066-71	2.2	60
2144	Effectiveness of Early Chemotherapy Treatment in Anaplastic Astrocytoma Patients. 1995 , 81, 424-428		1
2143	Therapy of malignant astrocytoma. 1995 , 13, 553-4		1
2142	Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. 1995 , 35, 118-22		42
2141	Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. 1996 , 32A, 636-40		75
2140	The Charing Cross Hospital experience with temozolomide in patients with gliomas. 1996 , 32A, 2236-41		122
2139	Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. 1996 , 32A, 2229-35		37
2138	Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old?. 1996 , 32A, 2193-4		10
2137	Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. <i>Journal of Clinical Oncology</i> , 1996 , 14, 945-54	2.2	65
2136	Salvage chemotherapy for oligodendroglioma. 1996 , 1, E1		3
2135	Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. 1996 , 7, 205-7		49

2134	Pre-radiation chemotherapy for malignant glioma in adults. 1996 , 23, 123-7		29
2133	Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. 1996 , 30, 247-55		15
2132	Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. 1996 , 27, 157-62		14
2131	Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. 1996 , 14, 203-6		27
2130	The role of chemotherapy in recurrent malignant gliomas: an overview. 1996 , 14, 551-9		58
2129	Stereotactic radiosurgery for metastatic brain tumors. 1996 , 8, 617-24		
2128	Radiation response and survival time in patients with glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 1996 , 84, 442-8	3.2	116
2127	Adjuvant combined modality therapy for malignant meningiomas. <i>Journal of Neurosurgery</i> , 1996 , 84, 733-6	3.2	92
2126	Salvage chemotherapy for oligodendroglioma. <i>Journal of Neurosurgery</i> , 1996 , 85, 597-601	3.2	48
2125	Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. <i>Journal of Neurosurgery</i> , 1997 , 87, 516-24	3.2	203
2124	Chemotherapy response criteria in malignant glioma. 1997 , 48, 1336-40		61
2123	Challenges in the design and conduct of phase III brain tumor therapy trials. 1997 , 49, 912-7		38
2122	Concurrent carboplatin and iodine-125 brachytherapy for recurrent glioblastoma multiforme. 1997 , 11, 199-205		3
2121	Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. 1997 , 3, E3		
2120	Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. 1997 , 33, 1592-6		175
2119	Chronic oral VP-16 for recurrent medulloblastoma. 1997 , 17, 230-4		48
2118	Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. 1997 , 3, 1354-61		591
2117	All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. 1997 , 34, 169-77		46

2116	Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study. 1997 , 32, 45-55		16
2115	Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. 1997 , 35, 39-45		10
2114	Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. 1997 , 40, 484-8		180
2113	Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. 1998 , 38, 69-75		41
2112	Significant change in tests of neurological impairment in patients with brain tumours. 1998 , 39, 81-90		14
2111	Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. 1998 , 37, 155-60		17
2110	Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. 1998 , 40, 251-5		12
2109	Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. 1998 , 82, 355-61		34
2108	Chemotherapie maligner Gliome. 1998 , 4, 618-621		
2107	Biologic activity of tamoxifen at low doses in healthy women. 1998 , 90, 1461-7		92
2106	Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. 1998 , 90, 1468-73		68
2105	Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. 1998 , 51, 1140-5		165
2104	Low-grade gliomas in children: tumor volume response to radiation. <i>Journal of Neurosurgery</i> , 1998 , 88, 969-74	3.2	37
2103	Pitfalls in the management of patients with malignant gliomas. 1998 , 18, 257-65		6
2102	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. 1998 , 90, 1473-9		1526
2101	Intra-Ocular Lymphoma with and without CNS Involvement: Diagnosis and Follow-up a Report of 15 Cases Studied by MR. 1998 , 11, 161-170		1
2100	Bias, benefit, or both: evaluating new glioma therapies. 1998 , 4, e9		1
2099	Low-grade gliomas in children: tumor volume response to radiation. 1998 , 4, e5		8

2098	Quality of life in patients with brain tumor: what's relevant in our quest for therapeutic efficacy. 1998 , 4, E8		8
2097	Malignant glioma: should chemotherapy be overthrown by experimental treatments?. 1998 , 9, 589-600		51
2096	PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. 1998 , 43, 1066-73		142
2095	Irinotecan therapy in adults with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1516-25	2.2	303
2094	Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. <i>Journal of Clinical Oncology</i> , 1999 , 17, 645-50	2.2	75
2093	New Treatment Strategies for Malignant Gliomas. 1999 , 4, 209-224		121
2092	Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. 1999 , 56, 703-8		51
2091	Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. 1999 , 53, 1119-22		123
2090	The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. <i>Neuro-Oncology</i> , 1999 , 1, 196-203	1	15
2089	A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. 1999 , 43, 293-8		136
2088	Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52. 1999 , 43, 559-63		70
2087	Comparison of Methods for Response Analysis of Central Nervous System Neoplasms. 1999 , 2, 153-161		2
2086	Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. 1999 , 41, 151-7		19
2085	Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. 1999 , 43, 161-6		27
2084	AIDS-related central nervous system lymphomas. 1999 , 43, 269-76		58
2083	Treatment of malignant gliomas in the elderly. 1999 , 43, 187-93		46
2082	Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. 1999 , 43, 71-8		35
2081	Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation. 1999 , 43, 173-8		22

2080	Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. 1999 , 44, 137-45		42
2079	Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. 1999 , 45, 159-65		13
2078	Chemotherapy for advanced CNS ependymoma. 1999 , 45, 61-7		48
2077	Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. 1999 , 44, 210-6		7
2076	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. 1999 , 20, 43-8		23
2075	Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center. 1999 , 71, 167-70		13
2074	Chemotherapy in adult malignant glioma. 1999 , 33, 174-91		1
2073	Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. 1999 , 44, 270-8; discussion 278-9		48
2072	Feature extraction for MRI segmentation. 1999 , 9, 85-90		15
2071	Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2762-71	2.2	625
2070	Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2572-8	2.2	760
2069	High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study. 2000 , 27, 302-6		15
2068	Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy?. 2000 , 21, 259-67		13
2067	Chemotherapy in patients with recurrent and progressive central neurocytoma. 2000 , 88, 169-74		90
2066	A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. 2000 , 44, 84-7		3
2065	In regard to Dr. Kondziolka et al.: stereotactic radiosurgery plus whole brain radiotherapy alone for patients with multiple brain metastases. 2000 , 47, 850-1		1
2064	Preliminary report of a phase I study of combined fractionated stereotactic radiosurgery and conventional external beam radiation therapy for unfavorable gliomas. 2000 , 48, 421-6		19
2063	Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. 2000 , 7, 859-66		514

2062	Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. 2000 , 47, 59-63		15
2061	Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. 2000 , 50, 245-9		30
2060	Treosulfan chemotherapy for recurrent malignant glioma. 2000 , 49, 231-4		9
2059	Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults. 2000 , 49, 141-5		3
2058	Hydroxyurea chemotherapy for unresectable or residual meningioma. 2000 , 49, 165-70		85
2057	Brain tumor clinical trials: pitfalls and promise for the future. 2000 , 2, 473-5		2
2056	A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. 2000 , 247, 297-302		44
2055	Embryonal tumors in the adult population: implications in therapeutic planning. 2000 , 21, 23-30		9
2054	Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2000 , 18, 708-15	2.2	377
2053	Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. <i>Neuro-Oncology</i> , 2000 , 2, 114-9		21
2052	Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. 2000 , 92, 2029-36		558
2051	A comparison of treatment results for recurrent malignant gliomas. 2000 , 26, 397-409		128
2050	Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. 2000 , 36, 1026-31		32
2049	Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. 2001 , 59, 127-37		88
2048	Radiotherapy for brain metastases: defining palliative response. 2001 , 61, 71-6		43
2047	Cáncer del sistema nervioso central. 2001 , 8, 3014-3023		
2046	An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. 2001 , 8, 325-7		24
2045	Current and future developments in the use of temozolomide for the treatment of brain tumours. 2001 , 2, 552-60		410

2044	Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. 2001 , 24, 117-21		51
2043	[Recommendations on the multidisciplinary management in patients with malignant glioma]. 2001 , 116, 271-5		1
2042	Brainstem gliomas in adults: prognostic factors and classification. 2001 , 124, 2528-39		176
2041	Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 742-9	2.2	254
2040	PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. 2001 , 28, 215-23		25
2039	Clinical trials in neuro-oncology. 2001 , 14, 689-94		7
2038	Age and radiation response in glioblastoma multiforme. 2001 , 49, 1288-97; discussion 1297-8		64
2037	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. 2001 , 12, 255-7		68
2036	Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2189-200	2.2	177
2035	Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. 2001 , 12, 259-66		280
2034	Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. 2001 , 60, 134-40		78
2033	Brain metastases from unknown primary tumour: a prospective study. 2001 , 248, 394-8		55
2032	Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. 2001 , 127, 91-5		27
2031	CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. 2001 , 50, 457-64		74
2030	Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. 2001 , 91, 423-7		29
2029	Lipid-associated sialoprotein in the cerebrospinal fluid: association with brain malignancies. 2001 , 92, 856-62		4
2028	Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. 2001 , 92, 1936-42		123
2027	Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. 2001 , 52, 149-56		12

2026	TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. 2001 , 52, 263-72		30
2025	Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. 2001 , 53, 27-32		19
2024	Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. 2001 , 54, 39-47		18
2023	PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. 2001 , 55, 45-50		8
2022	Thalidomide as an anti-angiogenic agent in relapsed gliomas. 2001 , 51, 41-5		66
2021	Molecular genetic alterations in glioblastomas with oligodendroglial component. 2001 , 101, 311-20		89
2020	Neuro-oncology clinical trials: promise and pitfalls. 2001 , 12, 149-50		5
2019	Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. 2001 , 56, 1219-21		66
2018	Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. 2001 , 71, 118-22		34
2017	PCV chemotherapy for recurrent glioblastoma multiforme. 2001 , 56, 118-20		93
2016	Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments. <i>Journal of Clinical Oncology</i> , 2002 , 20, 231-236	2.2	90
2015	Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". 2002 , 61, 58-63		116
2014	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. 2002 , 13, 777-80		25
2013	The radiation oncologist's perspective on stereotactic radiosurgery. 2002 , 1, 43-9		6
2012	A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. 2002 , 58, 1759-64		25
2011	Etoposide for recurrent spinal cord ependymoma. 2002 , 58, 1310-1		39
2010	Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. 2002 , 13, 163-7		18
2009	Intratumoral doxorubicin in patients with malignant brain gliomas. 2002 , 25, 60-4		68

2008	Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. <i>Journal of Neurosurgery</i> , 2002 , 97, 341-6	3.2	126
2007	Temozolomide. 2002 , 1, 55-80		63
2006	The use of temozolomide in recurrent malignant gliomas. 2002 , 28, 115-20		21
2005	Moving targets and ghosts of the past: outcome measurement in brain tumour therapy. 2002 , 9, 109-12		22
2004	EORTC Brain Tumor Group: achievements and perspectives. 2002 , 38 Suppl 4, S35-8		1
2003	Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. 2002 , 38, 1348-50		38
2002	Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. <i>Journal of Clinical Oncology</i> , 2002 , 20, 231-6	2.2	125
2001	Temozolomide in Glioblastoma Multiforme of the Elderly. 2002 , 88, S69-S70		1
2000	Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. 2002 , 63, 38-41		51
1999	German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. 2002 , 51, 247-52		140
1998	Gliomatosis cerebri: molecular pathology and clinical course. 2002 , 52, 390-9		66
1997	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. 2002 , 52, 842-5		29
1996	N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. 2002 , 52, 845-9		36
1995	Treatment of intracranial metastatic esthesioneuroblastoma. 2002 , 95, 243-8		40
1994	Salvage chemotherapy for recurrent spinal cord ependymoma. 2002 , 95, 997-1002		70
1993	Local injection of the ⁹⁰ Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. 2002 , 29, 486-93		80
1992	Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma. 2002 , 249, 1055-7		7
1991	Management of brain metastases. 2002 , 249, 1357-69		277

1990	Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. 2002 , 56, 183-8	59
1989	Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. 2002 , 57, 241-5	11
1988	Temozolomide as second-line chemotherapy for relapsed gliomas. 2002 , 57, 247-51	22
1987	Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. 2002 , 59, 81-90	13
1986	Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. 2002 , 59, 157-63	20
1985	Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. 2002 , 59, 151-5	24
1984	Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III. 2002 , 59, 231-7	20
1983	Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. 2003 , 64, 271-8	54
1982	A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. 2003 , 21, 473-80	6
1981	Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. 2003 , 62, 135-44	102
1980	Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. 2003 , 115, 389-97	10
1979	[Neurooncology]. 2003 , 74, 1139-49	1
1978	Oligodendroglione. 2003 , 9, 729-738	
1977	Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. 2003 , 70, 219-24	85
1976	Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. 2003 , 30, 39-44	13
1975	New frontiers in the treatment of malignant glioma. 2003 , 30, 72-6	15
1974	A prospective study on glioblastoma in the elderly. 2003 , 97, 657-62	148
1973	Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. 2003 , 97, 1276-84	167

1972	Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. 2003 , 97, 1963-8		40
1971	Salvage therapy in patients with glioblastoma: is there any benefit?. 2003 , 98, 2678-86		54
1970	Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. 2003 , 88, 496-501		14
1969	The role of chemotherapy in brain metastases. 2003 , 39, 2114-20		94
1968	Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2525-8	2.2	256
1967	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. 2003 , 14, 599-602		129
1966	Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4489-95 ²		362
1965	European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. 2003 , 14, 1732-4		33
1964	Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3559-65	2.2	40
1963	Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1044-9	2.2	435
1962	Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. 2003 , 89, 1172-9		217
1961	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2299-304	2.2	154
1960	Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. <i>Journal of Clinical Oncology</i> , 2003 , 21, 251-5	2.2	205
1959	Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. 2003 , 14, 1722-6		207
1958	Interobserver variability in the radiological assessment of response to chemotherapy in glioma. 2003 , 60, 826-30		79
1957	Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2305-11	2.2	135
1956	Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. 2003 , 14, 603-14		63
1955	Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. 2003 , 14, 1727-31		27

1954	Glioma therapies: how to tell which work?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3547-9	2.2	22
1953	The role of gamma knife radiosurgery in the treatment of primary and metastatic brain tumors. 2003 , 15, 188-96		24
1952	Survival and prognostic factors of patients with unresectable glioblastoma multiforme. 2003 , 14, 305-12		33
1951	. 2003 , 26, e22-e27		1
1950	Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme. 2003 , 14, 137-43		12
1949	Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. 2003 , 14, 437-42		25
1948	Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. 2003 , 9, 205-13		37
1947	Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. 2003 , 53, 577-86; discussion 586-8		93
1946	Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. 2003 , 14, e3		111
1945	Response to a phase II study of concomitant-to-sequential use of etoposide and radiation therapy in newly diagnosed malignant gliomas. 2003 , 26, e22-7		7
1944	Primary brain lymphomas after kidney transplantation: presentation and outcome. 2003 , 76, 930-7		85
1943	Preradiation Chemotherapy with VM-26 and CCNU in Patients with Glioblastoma Multiforme. 2004 , 90, 562-566		7
1942	Adult neoplasia: overview. 2004 , 279-287		
1941	How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. 2004 , 63, 1281-4		109
1940	Initial chemotherapy in gliomatosis cerebri. 2004 , 63, 270-5		92
1939	Gliomatosis cerebri: better definition, better treatment. 2004 , 63, 204-5		10
1938	Brain edema in neurooncology: radiological assessment and management. 2004 , 27, 261-6		36
1937	Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2004 , 6, 38-43	1	47

1936	Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , 2004 , 22, 4779-86	2.2	101
1935	Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. <i>Neuro-Oncology</i> , 2004 , 6, 247-52	1	20
1934	Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. 2004 , 15, 161-71		22
1933	First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1598-604	2.2	83
1932	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. 2004 , 63, 904-6		71
1931	Correlation of the response of recurrent malignant gliomas treated with interferon β with tumor interferon β gene content. 2004 , 25, 419		
1930	Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. 2004 , 10, 3728-36		337
1929	Temozolomide for treatment-resistant recurrent meningioma. 2004 , 62, 1210-2		134
1928	Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. 2004 , 63, 535-7		285
1927	Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. 2004 , 91, 1038-44		45
1926	Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. 2004 , 22, 427-35		78
1925	Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. 2004 , 66, 203-8		54
1924	Temozolomide as first-line agent in treating high-grade gliomas: phase II study. 2004 , 67, 77-81		26
1923	Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. 2004 , 67, 191-200		76
1922	Non-resectable slow-growing meningiomas treated by hydroxyurea. 2004 , 67, 221-6		80
1921	Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy—a phase-II study. 2004 , 68, 79-86		17
1920	Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. 2004 , 70, 37-48		13
1919	Prospective clinical trials of brain tumor therapy: the critical role of neurosurgeons. 2004 , 69, 151-67		4

1918	Long term course of WHO grade II astrocytomas of the Insula of Reil after I-125 interstitial irradiation. 2004 , 251, 1455-64	28
1917	Diffusion imaging for evaluation of tumor therapies in preclinical animal models. 2004 , 17, 249-59	99
1916	High grade gliomas. Multidisciplinary treatment with radiotherapy and concurrent carmustine after surgery. 2004 , 6, 207-211	
1915	Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. 2004 , 60, 353-7	122
1914	Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). 2004 , 70, 359-69	25
1913	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. 2004 , 100, 807-13	33
1912	Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 2004 , 100, 1213-20	46
1911	Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. 2004 , 100, 1199-207	163
1910	Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. 2004 , 100, 1712-6	45
1909	Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. 2004 , 100, 2208-14	118
1908	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. 2004 , 101, 2079-85	35
1907	Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. 2004 , 59, 501-8	77
1906	Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. 2004 , 16, 339-44	20
1905	Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. 2004 , 18, 495-9	64
1904	Temozolomide treatment in glioma--experiences in two university hospitals in Finland. 2004 , 43, 579-84	3
1903	Neuroimaging in glioma therapy. 2004 , 4, 665-71	5
1902	ALS lessons learned from other neurological diseases. Neuro-oncology. 2004 , 5 Suppl 1, 34-5	1
1901	One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. 2004 , 62, 2113-5	140

1900	[The blood-brain barrier should not be underestimated in neuro-oncology]. 2004 , 160, 523-32	19
1899	Tumeurs cranioencéphaliques. Techniques d'imagerie et sŕniologie. 2004 , 1, 604-620	1
1898	[Indications for how and when to treat low grade gliomas]. 2004 , 160, 507-9	0
1897	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. 2004 , 40, 1682-8	99
1896	BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. 2004 , 11, 374-5	11
1895	Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. 2004 , 27, 33-8	71
1894	Phase II study of salvage therapy with high-dose tamoxifen and oral etoposide for recurrent malignant glioma. 2004 , 1, 53-60	1
1893	An update on oligodendroglial neoplasms. 2005 , 18, 639-44	8
1892	A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. 2005 , 61, 1454-9	42
1891	Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. 2005 , 128, 177-83	49
1890	Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. 2005 , 12, 835-48	107
1889	Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. 2005 , 103, 802-9	115
1888	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. 2005 , 104, 143-8	64
1887	Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. 2005 , 103, 2606-15	93
1886	Salvage temozolomide for prior temozolomide responders. 2005 , 104, 2473-6	69
1885	NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. 2005 , 57, 843-7	163
1884	Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. 2005 , 252, 291-9	58
1883	Optimal role of temozolomide in the treatment of malignant gliomas. 2005 , 5, 198-206	142

1882	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. 2005 , 23, 357-61		346
1881	Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. 2005 , 71, 271-6		19
1880	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. 2005 , 72, 125-31		36
1879	UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. 2005 , 71, 295-9		32
1878	A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. 2005 , 71, 301-5		31
1877	Radiotherapy and chemotherapy of brain metastases. 2005 , 75, 31-42		28
1876	Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. 2005 , 75, 215-20		15
1875	GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. <i>Neuro-Oncology</i> , 2005 , 7, 425-34	1	26
1874	Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. 2005 , 16, 1177-84		34
1873	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. 2005 , 16 Suppl 1, i64-5		37
1872	Gene expression profiles associated with treatment response in oligodendrogliomas. 2005 , 65, 11335-44		95
1871	Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5034-43	2.2	575
1870	Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. <i>Neuro-Oncology</i> , 2005 , 7, 183-8	1	18
1869	Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. <i>Journal of Neurosurgery</i> , 2005 , 102, 267-75	3.2	76
1868	Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. 2005 , 102, 16759-64		253
1867	Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?. 2005 , 28, 391-6		47
1866	Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. 2005 , 11, 5167-74		164
1865	Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. 2005 , 102, 5524-9		536

1864	Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5294-304	2.2	608
1863	Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1507-13	2.2	180
1862	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. 2005 , 11, 7841-50		224
1861	Health-related quality of life and symptom research in glioblastoma multiforme patients. 2005 , 5, 763-74		11
1860	Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. 2005 , 65, 1129-31		33
1859	Glucose metabolism in brain tumours can be estimated using [18F]2-fluorodeoxyglucose positron emission tomography and a population-derived input function scaled using a single arterialised venous blood sample. 2005 , 26, 1377-83		10
1858	MRI in treatment of adult gliomas. 2005 , 6, 167-75		85
1857	High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. 2005 , 6, 953-60		66
1856	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. 2005 , 352, 987-96		13703
1855	VH gene analysis of primary CNS lymphomas. 2005 , 228, 143-7		22
1854	Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. 2005 , 50, 247-54		60
1853	[Place of chemotherapy and radiotherapy in the management of oligodendrogliomas]. 2005 , 51, 379-92		1
1852	Gene therapy for malignant glioma: current clinical status. 2005 , 12, 585-98		163
1851	Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. 2005 , 11, 4160-7		264
1850	New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology. 2006 , 6, 1129-31		2
1849	Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2715-22	2.2	583
1848	Oligodendroglial tumors. 2006 , 6, 519-32		7
1847	[Cerebral gliomas: imaging diagnosis and follow-up]. 2006 , 87, 779-91		4

1846	Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4412-7	2.2	131
1845	Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2707-14	2.2	592
1844	Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. 2006 , 17, 129-39		154
1843	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. 2006 , 42, 2499-503		103
1842	Phase II study of two-weekly temozolomide in patients with high-grade gliomas. 2006 , 13, 18-22		10
1841	Chemotherapy of High-Grade Astrocytomas. 2006 , 347-363		
1840	Temozolomide chemotherapy in patients with recurrent malignant gliomas. 2006 , 21, 739-44		11
1839	Clinical Trial Design and Implementation. 2006 , 105-112		
1838	Glioma and Other Neuroepithelial Neoplasms. 2006 , 674-694		
1837	Combined modality treatment of glioblastoma multiforme: the role of temozolomide. 2006 , 1, 43-51		15
1836	Primary lymphoma of the nervous system. 2006 , 12, 1-13		8
1835	Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. 2006 , 59, 988-99; discussion 999-1000		56
1834	A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. 2006 , 16, 1117		2
1833	Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. 2006 , 47, 37-41		20
1832	A prospective PET study of patients with glioblastoma multiforme. 2006 , 113, 412-8		2
1831	Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. 2006 , 95, 1424-31		9
1830	Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. 2006 , 60, 181-93		85
1829	Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. 2006 , 64, 869-75		30

1828	Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. 2006 , 65, 1429-39	38
1827	Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. 2006 , 66, S26-S32	25
1826	Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years. 2006 , 77, 219-20	3
1825	Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. 2006 , 77, 279-84	59
1824	Systemic high-dose intravenous methotrexate for central nervous system metastases. 2006 , 78, 255-60	94
1823	Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. 2006 , 78, 85-90	38
1822	Salvage chemotherapy with CPT-11 for recurrent meningioma. 2006 , 78, 271-6	74
1821	Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. 2006 , 78, 277-80	44
1820	Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. 2006 , 78, 295-302	95
1819	A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. 2006 , 78, 311-6	38
1818	Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. 2006 , 79, 299-305	13
1817	Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. 2006 , 80, 159-65	127
1816	Anaplastische Gliome. 2006 , 12, 508-517	
1815	Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study. 2006 , 118, 230-8	5
1814	Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. 2006 , 48, 703-13	89
1813	Use of ¹¹ C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. 2006 , 33, 516-24	116
1812	Thallium-201 SPECT: the optimal prediction of response in glioma therapy. 2006 , 33, 222-7	9
1811	Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. 2006 , 85, 45-50	43

1810	Advances in the treatment of primary brain tumors: dawn of a new era?. 2006 , 8, 45-9		7
1809	A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. 2006 , 6, 29		22
1808	Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. 2006 , 106, 172-9		19
1807	Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. 2006 , 106, 1372-81		49
1806	Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. 2006 , 12, 3843-50		111
1805	Does temsirolimus have a role in recurrent glioblastoma multiforme?. 2006 , 3, 70-1		3
1804	Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. 2006 , 5, 375-9		125
1803	Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4746-53	2.2	156
1802	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. <i>Neuro-Oncology</i> , 2006 , 8, 253-60	1	59
1801	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2006 , 8, 60-6	1	159
1800	Measures of response: RECIST, WHO, and new alternatives. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3245-51	2.2	243
1799	Changing paradigms--an update on the multidisciplinary management of malignant glioma. 2006 , 11, 165-80		316
1798	Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future. 2006 , 7, 749-65		4
1797	Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. 2006 , 12, 4899-907		361
1796	Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. <i>Neuro-Oncology</i> , 2006 , 8, 38-46	1	141
1795	Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. 2006 , 66, 1661-7		39
1794	Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. <i>Neuro-Oncology</i> , 2006 , 8, 156-65	1	101
1793	High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3865-70	2.2	234

1792	Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. 2006 , 67, 156-8		149
1791	Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. <i>Journal of Neurosurgery</i> , 2006 , 105, 385-91	3.2	74
1790	Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. 2006 , 13, 221-8		259
1789	Temozolomide: a milestone in neuro-oncology and beyond?. 2006 , 6, 1187-204		64
1788	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). 2006 , 95, 1155-60		193
1787	Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. 2006 , 95, 862-8		22
1786	Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1470-5	2.2	159
1785	Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. 2007 , 37, 897-906		48
1784	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4722-9	2.2	1119
1783	Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 2007 , 13, 1253-9		896
1782	Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. 2007 , 104, 10152-7		507
1781	Taming glioblastoma: targeting angiogenesis. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4705-6	2.2	35
1780	Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4714-21	2.2	352
1779	Temozolomide as salvage treatment in primary brain lymphomas. 2007 , 96, 864-7		118
1778	Molecularly targeted therapies for malignant gliomas: advances and challenges. 2007 , 7, 641-61		32
1777	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). 2007 , 96, 1047-51		156
1776	Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. <i>Neuro-Oncology</i> , 2007 , 9, 354-63	1	92
1775	Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. 2007 , 72, 302-7		22

1774	Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. 2007 , 30, 361-6		34
1773	Diagnostische und therapeutische Strategien bei rezidivierten Gliomen. 2007 , 34, 564-569		1
1772	Primary CNS lymphoma. 2007 , 3, 24-35		78
1771	Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. 2007 , 73, 21-5		55
1770	Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3357-61	2.2	208
1769	Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. 2007 , 13, 2606-13		123
1768	Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2007 , 18 Suppl 2, ii69-70		11
1767	Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2007 , 9, 70-4	1	13
1766	Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. 2007 , 69, 1366-73		93
1765	Lessons learned in the development of targeted therapy for malignant gliomas. 2007 , 6, 1909-19		162
1764	Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. 2007 , 61, E880-2; discussion E882		33
1763	^{99m} Tc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. 2007 , 28, 888-94		15
1762	New molecular targets in malignant gliomas. 2007 , 20, 712-8		30
1761	Inhibiting kinases in malignant gliomas. 2007 , 11, 473-96		34
1760	Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. 2007 , 17, 201-12		182
1759	Tumors of the Brain and Spine. 2007 ,		9
1758	The role of advanced MR imaging in understanding brain tumour pathology. 2007 , 21, 562-75		42
1757	Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. 2007 , 48, 1712-20		36

1756	Advanced MRI in the management of adult gliomas. 2007 , 21, 550-61	52
1755	Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. 2007 , 109, 751-60	65
1754	Anaplastic astrocytoma in adults. 2007 , 63, 72-80	59
1753	Predicting outcome of patients with high-grade gliomas after radiotherapy using quantitative analysis of T1-weighted magnetic resonance imaging. 2007 , 67, 1476-83	6
1752	Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. 2007 , 14, 391-8	53
1751	Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. 2007 , 7, 106	14
1750	Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status. 2007 , 183, 517-22	7
1749	Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. 2007 , 81, 287-94	73
1748	A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. 2007 , 82, 207-9	32
1747	GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials. 2007 , 82, 211-20	17
1746	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. 2007 , 82, 273-9	15
1745	Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. 2007 , 82, 281-8	68
1744	Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. 2007 , 85, 217-22	9
1743	Role of exclusive chemotherapy as first line treatment in oligodendroglioma. 2007 , 85, 319-28	8
1742	Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?. 2007 , 9, 60-71	32
1741	Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy. 2007 , 149, 1183-9; discussion 1189	10
1740	Metabolic deactivation of low-grade glioma during chemotherapy. 2007 , 254, 668-9	2
1739	Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. 2008 , 87, 143-51	29

1738	Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. 2008 , 86, 211-5	57
1737	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. 2008 , 87, 79-84	12
1736	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. 2008 , 88, 97-103	163
1735	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. 2008 , 88, 105-13	31
1734	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. 2008 , 89, 179-85	73
1733	A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. 2008 , 89, 187-93	12
1732	Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. 2008 , 89, 211-8	24
1731	CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. 2008 , 89, 231-8	16
1730	Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. 2008 , 90, 63-76	17
1729	Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. 2008 , 90, 89-97	91
1728	A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. 2008 , 90, 229-35	30
1727	Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. 2008 , 90, 293-9	20
1726	Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. 2008 , 35, 966-75	55
1725	The emerging role of anti-angiogenic therapy for malignant glioma. 2008 , 9, 1-22	27
1724	Natural history and management of brainstem gliomas in adults. A retrospective Italian study. 2008 , 255, 171-7	69
1723	Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. 2008 , 50, 227-30	90
1722	Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. 2008 , 112, 1139-46	52
1721	Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. 2008 , 112, 581-8	45

1720	Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). 2008 , 112, 1827-34	111
1719	Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. 2008 , 112, 2267-73	125
1718	Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. 2008 , 112, 2038-45	18
1717	Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. 2008 , 113, 405-10	336
1716	Temozolomide for recurrent low-grade spinal cord gliomas in adults. 2008 , 113, 1019-24	49
1715	Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. 2008 , 113, 2146-51	78
1714	Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. 2008 , 113, 2152-7	96
1713	A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. 2008 , 113, 2532-8	15
1712	Glioblastoma in adults. 2008 , 67, 139-52	126
1711	Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. 2008 , 20, 301-8	51
1710	Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. 2008 , 72, 383-9	78
1709	Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. 2008 , 70, 779-87	702
1708	Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. 2008 , 5, 1	24
1707	Response criteria for glioma. 2008 , 5, 634-44	150
1706	'Recurrent' glioblastoma multiforme, when should we reoperate?. 2008 , 22, 452-5	91
1705	Ensayos de quimiosensibilidad en cultivos primarios de tumores cerebrales. 2008 , 19, 5-10	1
1704	Short course of radiation therapy in elderly patients with glioblastoma multiforme. 2008 , 12, 788-92	16
1703	A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. 2008 , 26, 269-77	37

1702	Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. 2008 , 26, 33-44		14
1701	Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. 2008 , 8, 541-53		63
1700	Combination therapy for malignant glioma based on PTEN status. 2008 , 8, 1767-79		10
1699	[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 2008 , 164, 588-94		40
1698	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. 2008 , 14, 957-60		110
1697	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. 2008 , 14, 8205-12		288
1696	Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. 2008 , 14, 1124-30		18
1695	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008 , 10, 320-9	1	160
1694	Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. 2008 , 31, 435-9		5
1693	Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008 , 19 Suppl 2, ii83-5		13
1692	Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3387-94	2.2	231
1691	A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. 2008 , 16, 627-32		208
1690	Molecular imaging of brain tumors personal experience and review of the literature. 2008 , 8, 711-26		29
1689	Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4659-65	2.2	163
1688	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2008 , 10, 216-22	1	46
1687	3D conformal radiotherapy and cisplatin for recurrent malignant glioma. 2008 , 35, 57-64		15
1686	Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. 2008 , 14, 3098-104		204
1685	Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 2008 , 14, 7068-73		152

1684	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. <i>Neuro-Oncology</i> , 2008 , 10, 300-8	1	68
1683	Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5610-7	2.2	384
1682	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2192-7	2.2	641
1681	Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. <i>Journal of Clinical Oncology</i> , 2008 , 26, 271-8	2.2	231
1680	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. <i>Neuro-Oncology</i> , 2008 , 10, 361-7	1	188
1679	CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. 2008 , 14, 5626-34		59
1678	Brain tumor imaging in clinical trials. 2008 , 29, 419-24		139
1677	Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2008 , 10, 162-70	1	315
1676	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 1019-24	1	63
1675	Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. 2008 , 14, 2623-30		228
1674	Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 79-87	1	136
1673	Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. 2008 , 7, 333-9		67
1672	Gliomes de grade II. 2008 , 5, 1-17		1
1671	Chemotherapeutic wafers for High Grade Glioma. 2008 , CD007294		23
1670	Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. 2008 , 6, 515-22		61
1669	Temozolomide for high grade glioma. 2008 , CD007415		35
1668	Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. 2008 , 1, 863-7		16
1667	Neuroimaging in Monitoring the Therapy and Recurrence of Brain Tumors. 2008 , 21, 100-111		

1666	Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. 2008 , 21, 736-44		45
1665	Peritumoral apparent diffusion coefficient as a metric of response in patients with recurrent glioblastoma multiforme treated with bevacizumab and irinotecan. 2008 , 21, 350-61		4
1664	Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. 2008 , 19, 613-20		53
1663	Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. 2008 , 21, 728-35		47
1662	Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. 2008 , 63, 720-6; author reply 726-7		57
1661	Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. 2008 , 14, 279-85		51
1660	Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. 2010 , 4, 93-111		19
1659	Outcome of Newly Diagnosed Glioblastoma Patients Treated by Radiotherapy plus Concomitant and Adjuvant Temozolomide: A Long-Term Analysis. 2009 , 95, 191-197		42
1658	Epilepsy and insular Grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. 2009 , 27, E8		37
1657	Adult neoplasia. 289-294		
1656	Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3503-9	2.2	184
1655	IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. 2009 , 73, 1792-5		168
1654	Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2052-8	2.2	277
1653	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. 2009 , 8, 2773-9		209
1652	Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. 2009 , 161, 631-7		92
1651	FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. 2009 , 14, 1131-8		432
1650	Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4733-40	2.2	1864
1649	A phase I trial of enzastaurin in patients with recurrent gliomas. 2009 , 15, 3617-23		48

1648	Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. 2009 , 101, 615-20		38
1647	Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. 2009 , 101, 1995-2004		106
1646	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. <i>Neuro-Oncology</i> , 2009 , 11, 167-75	1	50
1645	Bevacizumab for recurrent ependymoma. 2009 , 73, 1677-80		49
1644	Quality of life in low-grade glioma patients receiving temozolomide. <i>Neuro-Oncology</i> , 2009 , 11, 59-68	1	59
1643	Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. 2009 , 15, 6683-93		158
1642	Phase II study of protracted daily temozolomide for low-grade gliomas in adults. 2009 , 15, 330-7		123
1641	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1262-7	2.2	226
1640	Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. 2009 , 73, 1200-6		253
1639	Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. <i>Neuro-Oncology</i> , 2009 , 11, 503-13	1	14
1638	Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. 2009 , 76, 184-9		15
1637	Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. <i>Journal of Neurosurgery</i> , 2009 , 111, 439-48	3.2	87
1636	Bidimensional measurements in brain tumors: assessment of interobserver variability. 2009 , 193, W515-22		41
1635	Noninvasive assessment of pediatric brain tumors. 2009 , 8, 1881-8		3
1634	Treatment options for recurrent glioblastoma: pitfalls and future trends. 2009 , 9, 613-9		29
1633	Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. 2009 , 18, 1549-57		43
1632	Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. <i>Journal of Neurosurgery</i> , 2009 , 110, 173-80	3.2	206
1631	Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5102-8	2.2	35

1630	A case of ALS-FTD in a large FALS pedigree with a K171 ANG mutation. 2009 , 72, 287-8		62
1629	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. 2009 , 20, 1596-1603		166
1628	Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. 2009 , 48, 52-8		86
1627	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. <i>Neuro-Oncology</i> , 2009 , 11, 550-5	1	139
1626	End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2905-8	2.2	203
1625	Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. 2009 , 72, 772-3; author reply 773-4		12
1624	Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2009 , 11, 556-61	1	26
1623	Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3861-7	2.2	137
1622	Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 740-5	2.2	1228
1621	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). <i>Neuro-Oncology</i> , 2009 , 11, 853-60	1	97
1620	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1268-74	2.2	429
1619	Angiogenesis as a therapeutic target in malignant gliomas. 2009 , 14, 621-36		87
1618	Bevacizumab and irinotecan for recurrent oligodendroglial tumors. 2009 , 72, 1601-6		64
1617	Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. <i>Radiology</i> , 2009 , 252, 182-9	20.5	271
1616	Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. 2009 , 9, 33		7
1615	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. 2009 , 9, 101		24
1614	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. 2009 , 9, 308		61
1613	Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. 2009 , 9, 372		101

1612	Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. 2009 , 9, 444	143
1611	Hypofractionated stereotactic radiotherapy for the treatment of brain metastases. 2009 , 115, 890-8	73
1610	Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. 2009 , 115, 1734-43	64
1609	Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. 2009 , 115, 2188-98	64
1608	Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. 2009 , 115, 2964-70	25
1607	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. 2009 , 115, 3512-8	179
1606	Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma. 2009 , 115, 4775-82	37
1605	Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme. 2009 , 29, 1199-205	24
1604	Intravoxel water diffusion heterogeneity imaging of human high-grade gliomas. 2010 , 23, 179-87	58
1603	Rechallenge with temozolomide in patients with recurrent gliomas. 2009 , 256, 734-41	80
1602	Antiangiogenic strategies for treatment of malignant gliomas. <i>Neurotherapeutics</i> , 2009 , 6, 513-26	6.4 30
1601	Stereotactic interstitial radiosurgery with the Photon Radiosurgery System (PRS) for metastatic brain tumors: a prospective single-center clinical trial. 2009 , 75, 1392-400	12
1600	Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. 2009 , 75, 164-9	18
1599	Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. 2009 , 91, 95-100	72
1598	A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). 2009 , 91, 175-82	84
1597	A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. 2009 , 91, 183-9	62
1596	Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. 2009 , 91, 299-305	86
1595	Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. 2009 , 91, 329-36	232

1594	Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. 2009, 91, 359-67	49
1593	ACNU-based chemotherapy for recurrent glioma in the temozolomide era. 2009, 92, 45-8	36
1592	Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. 2009, 92, 57-63	32
1591	Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. 2009, 92, 65-71	24
1590	A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. 2009, 92, 79-86	52
1589	An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. 2009, 92, 149-55	118
1588	Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. 2009, 92, 165-75	25
1587	Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. 2009, 94, 63-8	151
1586	Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. 2009, 94, 97-101	95
1585	Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. 2009, 93, 61-77	46
1584	Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. 2009, 95, 61-64	20
1583	Early metabolic responses in temozolomide treated low-grade glioma patients. 2009, 95, 87-93	83
1582	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. 2009, 95, 393-400	37
1581	Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. 2009, 9, 241-6	126
1580	Tumorprogress versus therapieinduzierte Veränderungen (Pseudoprogression) bei malignen Astrozytomen. 2009, 2, 16-18	
1579	Herausforderungen in der Diagnose und Behandlung von Rezidivgliomen. 2009, 2, 23-29	1
1578	Neuroradiologic review in pediatric brain tumor studies. 2009, 19, 263-73	22
1577	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). 2009, 64, 769-75	75

1576	Temozolomide in malignant gliomas: current use and future targets. 2009 , 64, 647-55	135
1575	Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). 2009 , 9, 1	140
1574	Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. 2009 , 29, 853-60	70
1573	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 2009 , 101, 1986-94	167
1572	Dendritic cell therapy of high-grade gliomas. 2009 , 19, 694-712	74
1571	A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. 2009 , 73, 222-7	44
1570	Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. 2009 , 75, 156-63	301
1569	Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. 2009 , 23, 170-8	57
1568	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 2009 , 45, 228-47	16132
1567	Quantitative imaging biomarkers in neuro-oncology. 2009 , 6, 445-54	79
1566	Antiangiogenic therapies for high-grade glioma. 2009 , 5, 610-20	204
1565	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5874-80 ^{2.2}	625
1564	Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 126-8	83
1563	Insights into pharmacotherapy of malignant glioma in adults. 2009 , 10, 2279-90	4
1562	Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy. 2009 , 91, 60-6	15
1561	Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1257-61	2.2 108
1560	Therapeutic advances in malignant glioma: current status and future prospects. 2009 , 19, 647-56	21
1559	L'Évaluation en oncologie : comment je fais en imagerie ?. 2009 , 49, 392-406	

1558	Neuroimaging in neuro-oncology. 2009 , 27, 171-201, ix		35
1557	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1275-9	2.2	249
1556	Classification and management of anaplastic gliomas. 2009 , 22, 650-6		10
1555	Treatment of recurrent high-grade gliomas. 2009 , 22, 657-64		22
1554	Pseudoprogession and pseudoresponse in the treatment of gliomas. 2009 , 22, 633-8		256
1553	The importance of surgical resection in malignant glioma. 2009 , 22, 645-9		68
1552	Évaluation par imagerie en cancérologie : de la définition des standards internationaux à l'exercice pratique. 2009 , 4, 1-12		
1551	Population-based study of pseudoprogession after chemoradiotherapy in GBM. 2009 , 36, 617-22		56
1550	Perfusion MRI of Brain Neoplasms. 2010 , 6, 232-245		1
1549	Gliomas: Current Issues in Diagnosis and Treatment. 2010 , 6, 285-294		
1548	Diffusion-weighted MRI for assessment of early cancer treatment response. 2010 , 11, 701-8		25
1547	Tumeurs hémisphériques intracrâniennes (approche nosologique et sémiologique en imagerie). 2010 , 5, 1-16		
1546	Pseudoprogession following chemoradiotherapy for glioblastoma multiforme. 2010 , 37, 36-42		89
1545	Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. 2010 , 31, 1135-43		71
1544	Imaging and response criteria in gliomas. 2010 , 22, 598-603		14
1543	Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. 2010 , 67, 87-93		20
1542	Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection. 2010 , 67, 1329-34		51
1541	Anti-angiogenic therapy for high grade glioma. 2010 ,		2

1540	Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. <i>Neuro-Oncology</i> , 2010 , 12, 466-72	1	77
1539	Short-term Radiotherapy followed by Adjuvant Chemotherapy in Poor-Prognosis Patients with Glioblastoma. 2010 , 96, 60-64		21
1538	Malignant gliomas: new translational therapies. 2010 , 77, 655-66		16
1537	Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. 2010 , 37, 84-92		77
1536	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. 2010 , 65, 391-7		23
1535	Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery. 2010 , 186, 127-34		20
1534	Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. 2010 , 186, 558-64		29
1533	[Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. 2010 , 81, 928-30, 932-5		1
1532	[Neuroradiological response criteria for malignant gliomas]. 2010 , 81, 950-5		6
1531	Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. 2010 , 77, 670-6		40
1530	Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. 2010 , 26, 1035-41		20
1529	The striate sign: peritumoural perfusion pattern of infiltrative primary and recurrent gliomas. 2010 , 33, 193-203; discussion 203-4		9
1528	Mise au point sur la pseudoprogression apr�s chimioradioth�rapie dans les glioblastomes. 2010 , 12, 559-564		1
1527	3'-Deoxy-3'-[(18)F]fluorothymidine and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study. 2010 , 44, 45-54		11
1526	Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. 2010 , 5, 183-91		21
1525	Vascular endothelial growth factor inhibitors in malignant gliomas. 2010 , 5, 167-74		9
1524	Recurrent high-grade glioma. 2010 , 12, 321-33		27
1523	Response assessment challenges in clinical trials of gliomas. 2010 , 12, 68-75		34

1522	Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. 2010 , 97, 157-8	17
1521	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. 2010 , 97, 389-92	59
1520	The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. 2010 , 97, 401-7	38
1519	Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results. 2010 , 98, 395-405	40
1518	Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. 2010 , 99, 49-56	88
1517	Up-front temozolomide in elderly patients with glioblastoma. 2010 , 99, 89-94	35
1516	Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. 2010 , 96, 211-7	121
1515	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 2010 , 96, 219-30	172
1514	[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. 2010 , 96, 231-9	59
1513	Salvage therapy with single agent bevacizumab for recurrent glioblastoma. 2010 , 96, 259-69	101
1512	Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. 2010 , 96, 393-402	111
1511	Extended-schedule dose-dense temozolomide in refractory gliomas. 2010 , 96, 417-22	41
1510	Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. 2010 , 96, 423-31	83
1509	Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. 2010 , 99, 103-13	16
1508	Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. 2010 , 99, 237-42	66
1507	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. 2010 , 100, 209-15	13
1506	Clinical, dosimetric, and radiographic correlation of radiation injury involving the brainstem and the medial temporal lobes following stereotactic radiotherapy for neoplasms of central skull base. 2010 , 98, 177-84	3
1505	Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme. 2010 , 98, 253-63	8

1504	Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. 2010 , 100, 407-15	45
1503	Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. 2010 , 9, 906-20	287
1502	BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. 2010 , 10, 30	59
1501	POSTER ABSTRACTS. 2010 , 6, 53-60	
1500	Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. 2010 , 116, 863-70	171
1499	Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. 2010 , 116, 1776-82	82
1498	Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. 2010 , 116, 3663-9	99
1497	A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. 2010 , 116, 5297-305	126
1496	Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. 2010 , 31, 538-48	202
1495	Functional diffusion map of malignant brain tumors: A surrogate imaging biomarker for early prediction of therapeutic response and patient survival. 2010 , 41, 441-451	3
1494	Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. 2010 , 51, 31-5	41
1493	Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. 2010 , 78, 85-90	68
1492	Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. 2010 , 54, 519-25	93
1491	Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. 2010 , 54, 538-45	49
1490	Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. 2010 , 55, 471-7	29
1489	Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. 2010 , 118, 585-94	27
1488	Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. 2010 , 30, 15-35	374
1487	Anti-angiogenic therapy for high grade glioma. 2010 ,	

1486	Role of bevacizumab therapy in the management of glioblastoma. 2010 , 97		1
1485	Bevacizumab plus irinotecan in treatment of recurrent brain gliomas. 2010 , 4, 253-258		
1484	Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. 2010 , 3, 79-85		4
1483	Gene Expression in Oligodendroglial Tumors. 2010 , 33, 81-94		3
1482	Progress on antiangiogenic therapy for patients with malignant glioma. 2010 , 2010, 689018		34
1481	A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. <i>Neuro-Oncology</i> , 2010 , 12, 500-7	1	20
1480	Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. <i>Neuro-Oncology</i> , 2010 , 12, 608-13	1	30
1479	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. <i>Neuro-Oncology</i> , 2010 , 12, 233-42	1	399
1478	Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1168-74	2.2	367
1477	Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. <i>Neuro-Oncology</i> , 2010 , 12, 595-602	1	25
1476	Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 2010 , 15, 1329-34		81
1475	Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. <i>Radiology</i> , 2010 , 256, 575-84	20.5	141
1474	Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. <i>Neuro-Oncology</i> , 2010 , 12, 908-16	1	25
1473	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2712-8	2.2	338
1472	Reply to W. Wick et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e190-e192	2.2	9
1471	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. <i>Neuro-Oncology</i> , 2010 , 12, 87-94	1	37
1470	O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. <i>Neuro-Oncology</i> , 2010 , 12, 283-8	1	99
1469	High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. <i>Neuro-Oncology</i> , 2010 , 12, 736-44	1	69

1468	Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2293-9	2.2	174
1467	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4722-9	2.2	593
1466	Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. <i>Neuro-Oncology</i> , 2010 , 12, 603-7	1	43
1465	Targeted toxins in brain tumor therapy. 2010 , 2, 2645-62		36
1464	A 31-year-old woman with a transformed low-grade glioma. 2010 , 303, 967-76		4
1463	Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). <i>Neuro-Oncology</i> , 2010 , 12, 855-61	1	151
1462	Current and emerging molecular targets in glioma. 2010 , 10, 1735-51		25
1461	Bevacizumab and recurrent malignant gliomas: a European perspective. <i>Journal of Clinical Oncology</i> , 2010 , 28, e188-9; author reply e190-2	2.2	92
1460	Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3048-53	2.2	251
1459	Angiogenesis in glioblastoma: just another moving target?. 2010 , 133, 955-6		8
1458	A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. <i>Neuro-Oncology</i> , 2010 , 12, 181-9	1	84
1457	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2010 , 12, 1300-10	1	171
1456	Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. <i>Neuro-Oncology</i> , 2010 , 12, 274-82	1	38
1455	A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 1167-72	1	21
1454	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , 2010 , 12, 401-8	1	147
1453	Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). 2010 , 21, 842-850		41
1452	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. <i>Neuro-Oncology</i> , 2010 , 12, 95-103	1	201
1451	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. <i>Neuro-Oncology</i> , 2010 , 12, 1061-70	1	88

1450	Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. 2010 , 32, 690-4		12
1449	Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. <i>Radiology</i> , 2010 , 255, 622-8	20.5	80
1448	Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. <i>Neuro-Oncology</i> , 2010 , 12, 508-16	1	107
1447	Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. <i>Neuro-Oncology</i> , 2010 , 12, 1152-61	1	33
1446	Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2010 , 112, 50-6	3.2	23
1445	Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations. <i>Journal of Neurosurgery</i> , 2010 , 113, 79-83	3.2	16
1444	[Advances in adults' gliomas biology, imaging and treatment]. 2010 , 97, 17-36		12
1443	Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3069-75	2.2	155
1442	Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. 2010 , 20, 425-48		14
1441	Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. 2010 , 21, 1723-1727		66
1440	Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. 2010 , 55, 3271-85		206
1439	Oligodendroglioma. 2010 , 163-169		
1438	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. 2010 , 9, 234		34
1437	Bevacizumab: in previously treated glioblastoma. 2010 , 70, 181-9		18
1436	Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 289-96	1	74
1435	High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v190-3		212
1434	Radiosurgery as Salvage Therapy for Primary Central Nervous System Lymphoma. 2010 , 276-287		
1433	[Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review]. 2010 , 56, 36-42		11

1432	[Chemotherapy and targeted treatments in glioblastomas]. 2010 , 56, 491-8		1
1431	[Clinical factors in glioblastoma and neuroradiology]. 2010 , 56, 449-54		1
1430	Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas. 2010 , 17, 842-8		17
1429	Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. 2010 , 17, 970-4		46
1428	EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. 2010 , 46, 348-54		64
1427	Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. 2010 , 112, 758-65		128
1426	Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2817-23	2.2	414
1425	Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. 2010 , 97, 382-6		68
1424	Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. 2010 , 97, 377-81		187
1423	Automatic segmentation and therapy follow-up of cerebral glioma in diffusion-tensor images. 2010 ,		
1422	Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1963-72	2.2	2543
1421	Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. 2011 , 11, 653-6		31
1420	Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. 2011 , 17, 4751-60		79
1419	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. 2011 , 11, 1713-7		2
1418	Evolution of care for patients with relapsed glioblastoma. 2011 , 11, 1719-29		5
1417	Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011 , 13, 660-8	1	80
1416	Methods of Cancer Diagnosis, Therapy, and Prognosis. 2011 ,		
1415	Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. 2011 , 76, 1918-24		136

1414	Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. 2011 , 82, 441-6		39
1413	High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma. 2011 , 52, 1882-90		12
1412	Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study. 2011 , 52, 1898-903		1
1411	Nouvelles imageries en neuro-oncologie au service du clinicien. 2011 , 2, 77-82		
1410	Opportunities and pitfalls of cancer imaging in clinical trials. 2011 , 8, 517-27		28
1409	High-Grade Gliomas: Dendritic Cell Therapy. 2011 , 313-333		
1408	Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. <i>Neuro-Oncology</i> , 2011 , 13, 1349-63	1	64
1407	Principles of Anticancer Drug Development. 2011 ,		
1406	Tumors of the Central Nervous System, Volume 2. 2011 ,		1
1405	Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience. 2011 , 113, 156-61		35
1404	Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. 2011 , 18, 1444-8		65
1403	The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. 2011 , 69, 893-905		430
1402	Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. 2011 , 12, 583-93		397
1401	Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. 2011 , 12, 1062-70		289
1400	Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. 2011 , 55, 603-10		34
1399	Immunotherapy for Malignant Gliomas: A Roadmap for the Future. 2011 ,		
1398	Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. 2011 , 18, e126-36		76
1397	Monitoring radiographic brain tumor progression. 2011 , 3, 191-200		23

1396	A novel method for volumetric MRI response assessment of enhancing brain tumors. 2011 , 6, e16031		36
1395	Immunotherapy for glioma: getting closer to the clinical arena?. 2011 , 24, 641-7		26
1394	Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. 2011 , 34, 382-9		135
1393	Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans. 2011 , 118, 3003-12		87
1392	Novel clinical trials in neuro-oncology. 2011 , 1, 781-794		1
1391	A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. 2011 , 9, 414-27		95
1390	IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. 2011 , 26, 1479-85		21
1389	Stereotactic 125iodine brachytherapy for the treatment of singular brain metastases: closing a gap?. 2011 , 68, 1209-18; discussion 1218-9		35
1388	Biopsy versus resection for the management of low-grade gliomas. 2011 ,		1
1387	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. 2011 , 41, 539-45		2
1386	T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. 2011 , 31, 2054-64		32
1385	Neuro-oncology: continuing multidisciplinary progress. 2011 , 10, 18-20		6
1384	Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. 2011 , 6, 83		39
1383	Therapeutic potential of anticancer immunotoxins. 2011 , 16, 495-503		80
1382	Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. <i>Neuro-Oncology</i> , 2011 , 13, 1331-8	1	57
1381	Glioblastoma: Temozolomide-Based Chemotherapy. 2011 , 243-248		
1380	Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. 2011 , 18, 2937-45		49
1379	Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4151-9	2.2	56

1378	Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. <i>Neuro-Oncology</i> , 2011 , 13, 1133-42	1	26
1377	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. 2011 , 101, 57-66		104
1376	Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. 2011 , 102, 95-103		61
1375	Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. 2011 , 102, 157-62		40
1374	A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. 2011 , 102, 247-53		31
1373	DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma. 2011 , 102, 261-71		20
1372	Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. 2011 , 102, 273-80		22
1371	Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. 2011 , 102, 311-6		88
1370	Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. 2011 , 102, 317-21		30
1369	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. 2011 , 102, 417-24		51
1368	Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. 2011 , 102, 427-32		32
1367	Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. 2011 , 102, 443-9		20
1366	Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme. 2011 , 103, 297-305		3
1365	Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. 2011 , 103, 325-32		72
1364	Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. 2011 , 103, 353-60		11
1363	Phase II study of sunitinib malate in patients with recurrent high-grade glioma. 2011 , 103, 491-501		99
1362	Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. 2011 , 103, 585-93		25
1361	Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. 2011 , 103, 611-8		110

1360	Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. 2011 , 103, 673-80	37
1359	Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. 2011 , 104, 205-14	77
1358	Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. 2011 , 104, 261-9	51
1357	Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. 2011 , 104, 287-91	51
1356	Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. 2011 , 104, 765-71	51
1355	Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). 2011 , 104, 801-9	10
1354	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. 2011 , 105, 91-101	32
1353	Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases. 2011 , 105, 109-18	24
1352	Should we reoperate for recurrent high-grade astrocytoma?. 2011 , 105, 291-9	7
1351	Salvage therapy with single agent bendamustine for recurrent glioblastoma. 2011 , 105, 523-30	21
1350	A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 2011 , 105, 601-6	15
1349	Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. 2011 , 105, 607-12	18
1348	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. 2011 , 105, 621-7	51
1347	O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. 2011 , 28, 127-35	26
1346	Hypofractionated stereotactic radiotherapy for oligometastases in the brain: a single-institution experience. 2011 , 32, 393-9	14
1345	Bevacizumab at recurrence in high-grade glioma. 2011 , 32 Suppl 2, S251-3	4
1344	Stereotactic LINAC radiosurgery for incompletely resected or recurrent atypical and anaplastic meningiomas. 2011 , 153, 1761-7	38
1343	Neuroradiologie bei Gliomen und Metastasen. 2011 , 17, 18-30	1

1342	[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme]. 2011 , 161, 13-9	2
1341	Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. 2011 , 187, 7-14	46
1340	Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. 2011 , 187, 722-8	18
1339	Neuroradiological response criteria for high-grade gliomas. 2011 , 21, 199-205	22
1338	Comparison of volumetric methods for tumor measurements on two and three dimensional MRI in adult glioblastoma. 2011 , 53, 565-9	6
1337	MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. 2011 , 53, 721-31	62
1336	ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. 2011 , 53, 291-302	83
1335	Gene expression in oligodendroglial tumors. 2011 , 34, 355-67	7
1334	Anti-angiogenic therapy in glioma. 2011 , 13, 294-300	5
1333	Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. 2011 , 13, 677-85	27
1332	Does gender matter in glioblastoma?. 2011 , 13, 737-41	7
1331	Pseudoprogression: relevance with respect to treatment of high-grade gliomas. 2011 , 12, 240-52	59
1330	Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. 2011 , 11, 305-12	43
1329	Response assessment in neuro-oncology. 2011 , 13, 50-6	88
1328	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. 2011 , 10, 128	223
1327	Evaluation of early imaging response criteria in glioblastoma multiforme. 2011 , 6, 121	15
1326	Detection of early response to temozolomide treatment in brain tumors using hyperpolarized ¹³ C MR metabolic imaging. 2011 , 33, 1284-90	97
1325	NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. 2011 , 70, 445-53	49

1324	Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. 2011 , 24, 734-49		74
1323	Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. 2011 , 59, 1205-12		26
1322	Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ^{111}In indium-octreotide imaging. 2011 , 117, 4506-11		17
1321	A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. 2011 , 117, 5548-59		27
1320	Prognostic value of early ^{18}F fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. 2011 , 80, 176-84		118
1319	L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. 2011 , 80, 369-76		69
1318	Molecular markers in low-grade gliomas: predictive or prognostic?. 2011 , 17, 4588-99		145
1317	Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. <i>Journal of Neurosurgery</i> , 2011 , 114, 613-23	3.2	208
1316	Targeted therapy for high-grade glioma with the TGF- β inhibitor trabedersen: results of a randomized and controlled phase IIb study. <i>Neuro-Oncology</i> , 2011 , 13, 132-42	1	290
1315	Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. <i>Journal of Neurosurgery</i> , 2011 , 114, 624-32	3.2	107
1314	[Radiological evaluation of tumor response in oncological studies (tumor response evaluation)]. 2011 , 183, 695-703		7
1313	Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. <i>Journal of Neurosurgery</i> , 2011 , 115, 248-55		39
1312	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 324-33	1	241
1311	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011 , 13, 401-9	1	81
1310	Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. <i>Neuro-Oncology</i> , 2011 , 13, 1244-51	1	57
1309	Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3611-9	2.2	114
1308	Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials. 2011 , 32, 794-7		33
1307	Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3050-5	2.2	167

1306	MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. <i>Neuro-Oncology</i> , 2011 , 13, 447-55	1	72
1305	Perfusion and permeability MR imaging of gliomas. 2011 , 10, 59-71		24
1304	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , 2011 , 13, 1364-9	1	268
1303	Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. 2011 , 76, 432-7		93
1302	Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). 2011 , 17, 346-52		42
1301	Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2689-95	2.2	172
1300	Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. <i>Neuro-Oncology</i> , 2011 , 13, 1118-24	1	81
1299	Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011 , 13, 143-51	1	56
1298	Rituximab monotherapy for patients with recurrent primary CNS lymphoma. 2011 , 76, 929-30		140
1297	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. <i>Neuro-Oncology</i> , 2011 , 13, 235-41	1	55
1296	Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (<i>Neuro-Oncology</i> 2011;13:132-142). <i>Neuro-Oncology</i> , 2011 , 13, 559-60; author reply 561-2	1	11
1295	Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. 2011 , 17, 4872-81		50
1294	Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e308-11	2.2	21
1293	Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. 2011 , 32, 882-9		148
1292	Irinotecan and bevacizumab in recurrent glioblastoma multiforme. 2011 , 12, 825-33		29
1291	Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?. 2011 , 11, 657-60		6
1290	International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2011 , 13, 649-59	1	110
1289	Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. <i>Neuro-Oncology</i> , 2011 , 13, 195-202	1	47

1288	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011 , 13, 1151-61 ¹	1	61
1287	Bevacizumab improves quality of life in patients with recurrent glioblastoma. 2011 , 2011, 602812		14
1286	Conventional MRI evaluation of gliomas. 2011 , 84 Spec No 2, S107-11		132
1285	Towards tailored therapy of glioblastoma multiforme. 2011 , 23, 187-99		16
1284	Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. 2011 , 84 Spec No 2, S179-95		3
1283	Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. 2011 , 22, 2144-2149		30
1282	A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. <i>Neuro-Oncology</i> , 2011 , 13, 1143-50	1	90
1281	Taming glioblastoma by targeting angiogenesis: 3 years later. <i>Journal of Clinical Oncology</i> , 2011 , 29, 124-62		22
1280	Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. 2011 , 32, 382-7		154
1279	Recurrent high-grade glioma: a diagnostic and therapeutic challenge. 2011 , 11, 509-18		19
1278	Corticosteroids in brain cancer patients: benefits and pitfalls. 2011 , 4, 233-42		184
1277	Computational approaches to assist in the evaluation of cancer treatment response. 2011 , 3, 233-246		3
1276	Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2011 , 13, 791-801	1	51
1275	A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 437-46	1	134
1274	Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 2011 , 84, 327-33		4
1273	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. <i>Neuro-Oncology</i> , 2011 , 13, 509-16	1	82
1272	Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 119-31 [†]		43
1271	Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. 2011 , 32, 1978-85		367

1270	Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. <i>Neuro-Oncology</i> , 2011 , 13, 546-57	1	33
1269	Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: a single center experience. 2011 , 68, 961-6		35
1268	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011 , 13, 353-61	1	90
1267	A Review of the Treatment Options in Recurrent Glioblastoma: Focus on Bevacizumab. 2011 , 3, 79-92		
1266	New agents and new end points for recurrent gliomas. <i>Journal of Clinical Oncology</i> , 2011 , 29, e245-6; author reply e247	2.2	5
1265	Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2307-13	2.2	227
1264	Advanced imaging of brain tumors. 2012 , 188-213		
1263	Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. <i>Neuro-Oncology</i> , 2012 , 14, 1404-12	1	42
1262	A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. 2012 , 85, 382-9		20
1261	Diffuse intrinsic pontine glioma: poised for progress. <i>Frontiers in Oncology</i> , 2012 , 2, 205	5.3	167
1260	Inhibiting angiogenesis in malignant gliomas. 2012 , 104, 279-308		
1259	Phase I study of terameprocol in patients with recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2012 , 14, 511-7	1	39
1258	Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. <i>Neuro-Oncology</i> , 2012 , 14, 79-86	1	23
1257	A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). <i>Neuro-Oncology</i> , 2012 , 14, 344-50	1	19
1256	A phase I/II trial of vandetanib for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2012 , 14, 1519-26	1	66
1255	Volumetric response evaluation after intensity modulated radiotherapy in patients with supratentorial gliomas. 2012 , 11, 41-8		1
1254	The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas. 2012 , 42, 270-7		30
1253	Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. <i>Neuro-Oncology</i> , 2012 , 14, 222-9	1	65

1252	3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. 2012 , 53, 29-36	110
1251	Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. 2012 , 53, 1048-57	156
1250	Palliative reirradiation for progressive diffuse intrinsic pontine glioma. 2012 , 35, 51-7	53
1249	Status quo--standard-of-care medical and radiation therapy for glioblastoma. 2012 , 18, 12-9	49
1248	Neuroimaging: diagnosis and response assessment in glioblastoma. 2012 , 18, 26-31	18
1247	Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. 2012 , 18, 273-9	93
1246	Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. 2012 , 18, 229-38	13
1245	Chemotherapy for Brain Tumors. 2012 , 94-104	
1244	Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. 2012 , 18, 2930-42	87
1243	Fluorescence-guided operation in recurrent glioblastoma multiforme treated with bevacizumab-fluorescence of the noncontrast enhancing tumor tissue?. 2012 , 73, 401-6	7
1242	Radiologische Evaluation des Tumoransprechens in ónkologischen Therapiestudien (Tumor Response Evaluation). 2012 , 33, 103-111	
1241	Resection and survival. <i>Journal of Neurosurgery</i> , 2012 , 116, 1169-70; discussion 1170-1	3.2
1240	Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study. 2012 , 33, 2095-102	26
1239	18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. <i>Neuro-Oncology</i> , 2012 , 14, 1079-89 ¹	84
1238	Avastin: more questions than answers. ... <i>Journal of Neurosurgery</i> , 2012 , 116, 336-40; discussion 340	3.2 1
1237	Bevacizumab as first-line therapy for glioblastoma. 2012 , 8, 929-38	5
1236	MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. 2012 , 33, 803-17	68
1235	[Use of amino acid PET in the Diagnostic and Treatment Management of cerebral gliomas]. 2012 , 80, 17-23	4

1234	Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date. 2012 , 12, 1413-27		13
1233	Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. 2012 , 198, 19-26		110
1232	Gliomatosis cerebri. 2012 , 105, 507-15		9
1231	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. <i>Neuro-Oncology</i> , 2012 , 14, 1511-8	1	82
1230	A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. 2012 , 51, 797-804		51
1229	Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. <i>Neuro-Oncology</i> , 2012 , 14, 919-30	1	152
1228	State of the art and perspectives in the treatment of glioblastoma. 2012 , 1, 49-70		4
1227	An innovative mathematical analysis of routine MRI scans in patients with glioblastoma using DoctorEye. 2012 ,		
1226	Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. <i>Neuro-Oncology</i> , 2012 , 14, 667-73	1	79
1225	Glioblastoma presenting with steroid-induced pseudoregression of contrast enhancement on magnetic resonance imaging. 2012 , 2012, 816873		3
1224	Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. 2012 , 35, 284-9		42
1223	Collaborative Labeling of Malignant Glioma with WebMILL: A First Look. 2012 , 8318,		
1222	Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. 2012 , 42, 887-95		75
1221	Anti-angiogenic approaches to malignant gliomas. 2012 , 12, 279-88		12
1220	Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab. 2012 , 4, 151-157		26
1219	Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature. 2012 , 23, 749-53		2
1218	Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. 2012 , 33, 563-70		29
1217	Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. 2012 , 70, 234-43; discussion 243-4		159

1216	Endpoints for clinical trials and revised assessment in neuro-oncology. 2012 , 25, 780-5		15
1215	Glioma and Other Neuroepithelial Neoplasms. 2012 , 767-794		
1214	Structural and Molecular Imaging in Cancer Therapy Clinical Trials. 2012 , 387-412		
1213	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2012 , 14, 1503-10	1	45
1212	Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. <i>Neuro-Oncology</i> , 2012 , 14, 215-21	1	160
1211	A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. 2012 , 30, 2344-51		25
1210	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. 2012 , 13, e196-204		43
1209	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. 2012 , 13, 707-15		792
1208	Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. 2012 , 109, 273-83		25
1207	Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis. 2012 , 109, 433-8		5
1206	A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. 2012 , 110, 111-8		61
1205	Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. 2012 , 110, 221-6		19
1204	Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. 2012 , 110, 237-43		26
1203	Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. 2012 , 110, 257-64		24
1202	Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 2012 , 82, 58-66		61
1201	Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. 2012 , 82, 51-7		19
1200	Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. 2012 , 82, 77-82		42
1199	Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. 2012 , 82, 749-55		60

1198	Encouraging early clinical outcomes with helical tomotherapy-based image-guided intensity-modulated radiation therapy for residual, recurrent, and/or progressive benign/low-grade intracranial tumors: a comprehensive evaluation. 2012 , 82, 756-64	11
1197	Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. 2012 , 82, 739-42	24
1196	Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. 2012 , 83, 93-9	106
1195	Chemotherapy: present and future. 2012 , 45, 471-86, x	6
1194	Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation. 2012 , 19, 977-85	30
1193	Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme. 2012 , 23, 417-27	11
1192	Therapeutic targeting of VEGF in the treatment of glioblastoma. 2012 , 16, 973-84	30
1191	Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. 2012 , 53, 1367-74	140
1190	Angiogenic inhibition in high-grade gliomas: past, present and future. 2012 , 12, 733-47	25
1189	Bevacizumab for the treatment of high-grade glioma. 2012 , 12, 1101-11	19
1188	Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. 2012 , 19, 1353-61	79
1187	Clinical trials in neuro-oncology. 2012 , 104, 417-34	1
1186	A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. 2012 , 33, 320-31	43
1185	Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. 2012 , 48, 896-903	18
1184	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. 2012 , 48, 1176-84	137
1183	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. 2012 , 48, 2192-202	492
1182	Measurement of tumor size in adult glioblastoma: classical cross-sectional criteria on 2D MRI or volumetric criteria on high resolution 3D MRI?. 2012 , 81, 2370-4	18
1181	MRI patterns in recurrence of primary CNS lymphoma in immunocompetent patients. 2012 , 81, 2380-5	12

1180	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. 2012 , 21, 1247-66	43
1179	MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. 2012 , 10, 250	58
1178	A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy. 2012 , 10, 90	9
1177	Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients. 2012 , 17, 25	48
1176	Radiopeptide Therapy of Brain Tumors. 2012 , 199-205	
1175	The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. 2012 , 56, 567-73	7
1174	Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment. 2012 , 81, 2805-10	29
1173	A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide. 2012 , 19, 1501-5	16
1172	3D Slicer as an image computing platform for the Quantitative Imaging Network. 2012 , 30, 1323-41	2965
1171	Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis. 2012 , 30, 1268-78	27
1170	Promise and pitfalls of quantitative imaging in oncology clinical trials. 2012 , 30, 1301-12	62
1169	Pseudoprogression and treatment effect. 2012 , 23, 277-87, viii-ix	22
1168	Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas. 2012 , 23, 269-76, viii	3
1167	Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. 2012 , 33, 1059-64	56
1166	Tumors of the Central Nervous System, Volume 8. 2012 ,	1
1165	The role of avastin in the management of recurrent glioblastoma. 2012 , 23, 331-41, x	11
1164	Diffusion-weighted MRI as a biomarker for treatment response in glioma. 2012 , 1, 169-80	37
1163	Alternative chemotherapeutic agents: nitrosoureas, cisplatin, irinotecan. 2012 , 23, 297-306, ix	13

1162 Clinical trials and chemotherapy. **2012**, 306-315

1161	Volumetry of [11C]-Methionine Positron Emission Tomographic Uptake as a Prognostic Marker before Treatment of Patients with Malignant Glioma. 2012 , 11, 7290.2012.00022	24
1160	Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. 2012 , 2012, 193436	11
1159	An observational study of the first experience with bevacizumab for the treatment of patients with recurrent high-grade glioma in two belgian university hospitals. 2012 , 2012, 801306	4
1158	Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma. 2012 , 19, 308-14	8
1157	Bevacizumab and etoposide combination chemotherapy in patients with recurrent malignant gliomas who failed bevacizumab. 2012 , 2, 6	1
1156	Current concepts in brain tumor imaging. 2012 , 119-24	1
1155	Biologic therapy for malignant glioma. 2012 , 102-113	
1154	Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. 2012 , 4, 799-801	8
1153	Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. 2012 , 12, 212-24	7
1152	Volumetric and MGMT parameters in glioblastoma patients: survival analysis. 2012 , 12, 3	51
1151	Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1358-63	2.2 158
1150	Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. 2012 , 59, 34-8	36
1149	Glufosfamide: can we improve the process of anticancer agent development?. 2012 , 21, 749-54	11
1148	Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. 2012 , 59, 511-7	79
1147	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. 2012 , 131, 1342-50	180
1146	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 2012 , 118, 4759-67	26
1145	Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. 2012 , 118, 3599-606	13

1144	Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. 2012 , 118, 3743-8	62
1143	LINAC-radiosurgery for nonsecreting pituitary adenomas. Long-term results. 2012 , 188, 319-25	27
1142	Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. 2012 , 188, 334-9	91
1141	Local progression and pseudo progression after single fraction or fractionated stereotactic radiotherapy for large brain metastases. A single centre study. 2012 , 188, 696-701	26
1140	[New criteria for assessment of response to treatment of gliomas]. 2012 , 52, 317-9	
1139	Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. 2012 , 107, 527-35	41
1138	Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. 2012 , 108, 173-7	48
1137	Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. 2012 , 108, 451-8	24
1136	Assessment of intra-observer variability in measurement of high-grade brain tumors. 2012 , 108, 477-83	19
1135	Development of a novel animal model to differentiate radiation necrosis from tumor recurrence. 2012 , 108, 411-20	22
1134	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. 2012 , 108, 491-8	134
1133	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. 2012 , 108, 499-506	36
1132	Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy. 2012 , 108, 521-5	9
1131	Papillary tumors of the pineal region: a novel therapeutic option-stereotactic 125iodine brachytherapy. 2012 , 109, 99-104	8
1130	MRI and thallium-201 SPECT in the prediction of survival in glioma. 2012 , 54, 539-46	7
1129	Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. 2012 , 69, 849-60	15
1128	Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. 2012 , 69, 1507-18	50
1127	MLC-LINAC radiosurgery for intracranial meningiomas of complex shape. 2012 , 154, 599-604	5

1126	The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. 2012 , 24, 216-27		28
1125	Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. <i>World Neurosurgery</i> , 2012 , 77, 130-4	2.1	68
1124	IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. 2012 , 103, 269-73		185
1123	Bevacizumab and daily temozolomide for recurrent glioblastoma. 2012 , 118, 1302-12		110
1122	Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. 2012 , 67, 237-45		34
1121	Radiotherapy with and without temozolomide in elderly patients with glioblastoma. 2012 , 188, 154-9		25
1120	A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. 2012 , 69, 505-14		9
1119	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. 2012 , 69, 281-7		11
1118	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. 2012 , 106, 111-9		56
1117	Phase II study of Gleevec [®] plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 2012 , 106, 409-15		62
1116	Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. 2012 , 106, 651-6		37
1115	A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. 2012 , 106, 611-7		12
1114	Corticosteroid-use in primary and secondary brain tumour patients: a review. 2012 , 106, 449-59		35
1113	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. 2012 , 107, 155-64		108
1112	Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. 2012 , 107, 315-21		63
1111	A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. 2012 , 107, 343-9		37
1110	Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. 2012 , 107, 395-405		50
1109	Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. 2012 , 154, 203-9		45

1108	Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding. 2012 , 154, 191-201; discussion 201	98
1107	The efficacy of temozolomide for recurrent glioblastoma multiforme. 2013 , 20, 223-30	37
1106	Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. 2013 , 8, 97	31
1105	Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. 2013 , 8, 52	41
1104	Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. 2013 , 115, 71-7	23
1103	Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. 2013 , 114, 237-40	102
1102	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. 2013 , 113, 397-401	16
1101	Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series. 2013 , 113, 27-32	5
1100	Seizures during the management of high-grade gliomas: clinical relevance to disease progression. 2013 , 113, 101-9	19
1099	Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging. 2013 , 112, 427-35	13
1098	Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?. 2013 , 112, 141-52	72
1097	Effects of slice thickness and head rotation when measuring glioma sizes on MRI: in support of volume segmentation versus two largest diameters methods. 2013 , 112, 165-72	11
1096	"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. 2013 , 112, 209-15	10
1095	Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. 2013 , 112, 247-55	41
1094	The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. 2013 , 112, 277-83	18
1093	Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates. 2013 , 112, 121-32	29
1092	Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. 2013 , 55, 361-9	81
1091	A radiologist's guide to treatment response criteria in oncologic imaging: functional, molecular, and disease-specific imaging biomarkers. 2013 , 201, 246-56	14

1090	Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. 2013 , 113, 403-9	27
1089	Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. 2013 , 60, 1397-401	53
1088	A survey of MRI-based medical image analysis for brain tumor studies. 2013 , 58, R97-129	505
1087	Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients. 2013 , 29, 1851-8	12
1086	Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). 2013 , 139, 829-35	9
1085	Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. 2013 , 125, 481-6	23
1084	Perfusion MRI: the five most frequently asked clinical questions. 2013 , 201, W495-510	71
1083	Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. 2013 , 13, 347	93
1082	Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. 2013 , 40, 22-33	136
1081	BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. 2013 , 125, 901-10	119
1080	Glioblastoma management in the temozolomide era: have we improved outcome?. 2013 , 115, 303-10	23
1079	[Late and prolonged pseudoprogression in serial posttreatment MRI due to use of new chemotherapy concepts to treat malignant glioblastoma]. 2013 , 189, 706-7	
1078	Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre. 2013 , 189, 456-61	7
1077	Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. 2013 , 19, 1178-83	169
1076	FLAIR lesion segmentation: application in patients with brain tumors and acute ischemic stroke. 2013 , 82, 1512-8	35
1075	[Criteria for radiological assessment of therapy response: criteria-based appraisal]. 2013 , 53, 322-8	
1074	Proton magnetic resonance spectroscopy predicts concurrent chemoradiotherapy response and time-to-progression in high-grade gliomas after surgery. 2013 , 44, 885-891	
1073	Imagerie de perfusion en pathologie cérébrale. 2013 , 94, 1238-1254	

1072	The treatment of glioblastomas: a systematic update on clinical Phase III trials. 2013 , 87, 265-82		25
1071	Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. 2013 , 18, 1052-66		11
1070	Impact of perfusion map analysis on early survival prediction accuracy in glioma patients. 2013 , 6, 766-74		21
1069	Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. <i>Neuro-Oncology</i> , 2013 , 15, 936-44	1	42
1068	Central Nervous System Neoplasia: Evidence-Based Medicine, Diagnosis, Treatment, and Complications. 2013 , 707-728		
1067	A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. 2013 , 49, 1634-40		11
1066	. 2013 ,		
1065	Perfusion imaging in brain disease. 2013 , 94, 1241-57		11
1064	Role of MRI perfusion in improving the treatment of brain tumors. 2013 , 5, 407-426		6
1063	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. 2013 , 2, 33-47		16
1062	Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. 2013 , 24, 3117-23		136
1061	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4085-91	2.2	623
1060	Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013 , 31, 337-43	2.2	767
1059	A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013 , 15, 1096-101	1	48
1058	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. 2013 , 14, e396-406		92
1057	Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. 2013 , 115, 267-76		27
1056	Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. 2013 , 13, 402		52
1055	Concurrent whole brain radiotherapy and bortezomib for brain metastasis. 2013 , 8, 204		13

1054	Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases. 2013 , 34, 647-53	9
1053	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. 2013 , 72, 1213-22	14
1052	Current and future directions for Phase II trials in high-grade glioma. 2013 , 13, 369-87	4
1051	IFN- γ for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. 2013 , 2, 227-35	24
1050	MRI perfusion in determining pseudoprogression in patients with glioblastoma. 2013 , 37, 41-9	94
1049	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. 2013 , 10, 14-26	247
1048	Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. 2013 , 23, 513-20	67
1047	Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. 2013 , 331, 139-46	191
1046	Application of Advanced MR Imaging Techniques and the Evolving Role of PET/MR Imaging in Neuro-oncology. 2013 , 8, 183-99	2
1045	Évaluation RECIST en cancérologie thoracique. 2013 , 5, 361-366	
1044	Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. 2013 , 85, 636-42	54
1043	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. 2013 , 81, 1515-22	160
1042	Ophthalmological outcome after resection of tumors based on the pineal gland. <i>Journal of Neurosurgery</i> , 2013 , 119, 420-6	3,2 12
1041	Tumores gliales del sistema nervioso: planificación y porcentaje de resección. 2013 , 5, 129-132	
1040	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. 2013 , 8, 201-17	5
1039	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. 2013 , 8, 163-82	4
1038	Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience. 2013 , 115, 1609-14	13
1037	MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study. 2013 , 82, e240-5	10

1036	Surgical resection of malignant gliomas-role in optimizing patient outcome. 2013 , 9, 141-51		106
1035	A phase II trial of oral gimatecan for recurrent glioblastoma. 2013 , 111, 347-53		15
1034	Posttreatment evaluation of central nervous system gliomas. 2013 , 21, 241-68		11
1033	Brain tumors: a multimodality approach with diffusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic susceptibility contrast and dynamic contrast-enhanced magnetic resonance imaging. 2013 , 21, 199-239		42
1032	Biopsy versus resection for the management of low-grade gliomas. 2013 , CD009319		17
1031	MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. 2013 , 27, 772-8		24
1030	Blood-based biomarkers for malignant gliomas. 2013 , 113, 345-352		28
1029	Update on bevacizumab and other angiogenesis inhibitors for brain cancer. 2013 , 18, 137-53		23
1028	MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-grade gliomas. 2013 , 57, 349-55		34
1027	Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma. 2013 , 82, e87-94		21
1026	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. 2013 , 15, 38-51		1
1025	Identification of early and distinct glioblastoma response patterns treated by boron neutron capture therapy not predicted by standard radiographic assessment using functional diffusion map. 2013 , 8, 192		8
1024	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. 2013 , 9, 1653-64		7
1023	Pseudoprogression after glioma therapy: a comprehensive review. 2013 , 13, 389-403		74
1022	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. <i>Journal of Clinical Oncology</i> , 2013 , 31, 344-50	2.2	800
1021	Validation study of a fast, accurate, and precise brain tumor volume measurement. 2013 , 111, 480-7		20
1020	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. 2013 , 49, 3477-85		43
1019	Defining pseudoprogression in glioblastoma multiforme. 2013 , 20, 1335-41		33

1018	Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. <i>Neuro-Oncology</i> , 2013 , 15, 442-50	1	32
1017	FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. 2013 , 85, 191-5		17
1016	Quantitative evaluation of multi-parametric MR imaging marker changes post-laser interstitial ablation therapy (LITT) for epilepsy. 2013 , 8671, 86711Y		4
1015	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , 2013 , 15, 1405-12	1	45
1014	Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. <i>Radiology</i> , 2013 , 266, 842-52	20.5	133
1013	MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. 2013 , 34, 1450-5		25
1012	Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. <i>Journal of Neurosurgery</i> , 2013 , 118, 821-9	3.2	25
1011	Emerging methods for disease monitoring in malignant gliomas. 2013 , 2, 511-22		10
1010	Bildgebende Beurteilung des Therapieansprechens unter Chemotherapie. 2013 , 13, 221-239		0
1009	Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab. 2013 , 34, 1752-1757		32
1008	Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. <i>Neuro-Oncology</i> , 2013 , 15, 515-34	1	201
1007	Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013 , 15, 930-51		60
1006	Cerebrotendinous Xanthomatosis: Report of two cases and a novel genetic mutation in an Indian patient. 2013 , 4, S87-90		2
1005	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. 2013 , 24, 3123-8		26
1004	Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. <i>Neuro-Oncology</i> , 2013 , 15, 945-54	1	53
1003	Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region. <i>Neuro-Oncology</i> , 2013 , 15, 1721-31	1	19
1002	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013 , 15, 490-6	1	63
1001	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3212-8	2.2	392

1000	The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. 2013 , 54, 1217-22		38
999	Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. 2013 , 43, 587-95		48
998	Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. 2013 , 73, 2976-86		47
997	A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. 2013 , 19, 900-8		85
996	Phase I study of GRN1005 in recurrent malignant glioma. 2013 , 19, 1567-76		108
995	Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. <i>Radiology</i> , 2013 , 269, 831-40	20.5	124
994	Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. 2013 , 69, 95-101		20
993	Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. 2013 , 23, 191-5		143
992	Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide : A mono-institutional experience of 215 patients. 2013 , 9, 381-6		12
991	Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. 2013 , 4, S46-55		17
990	Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. 2013 , 4, S265-88		201
989	Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. <i>Neuro-Oncology</i> , 2013 , 15, 607-17	1	50
988	Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics. <i>Neuro-Oncology</i> , 2013 , 15, 981-9	1	10
987	Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. <i>Neuro-Oncology</i> , 2013 , 15, 1395-404	1	56
986	Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. 2013 , 59, 176-80		13
985	Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. 2013 , 119, 2747-53		25
984	Reporting standards for endovascular chemotherapy of head, neck and CNS tumors. 2013 , 5, 396-9		2
983	Effects of perfusion on diffusion changes in human brain tumors. 2013 , 38, 868-75		5

982	GBM volumetry using the 3D Slicer medical image computing platform. <i>Scientific Reports</i> , 2013 , 3, 1364	4.9	134
981	Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. 2013 , 54, 2046-54		94
980	Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013 , 15, 242-50	1	71
979	Standards of care for treatment of recurrent glioblastoma--are we there yet?. <i>Neuro-Oncology</i> , 2013 , 15, 4-27	1	432
978	Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful?. 2013 , 12, 7290.2013.00056		13
977	Bevacizumab Alone at 5 mg/kg in an Every-3-Week Schedule for Patients with Recurrent Glioblastomas: A Single Center Experience. 2013 , 99, 601-603		9
976	Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasms. 2013 , 26, 396-412		16
975	Moderne Therapiestrategien bei hirneigenen glialen Tumoren. 2013 , 16, 32-43		
974	Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. 2013 , 37, 264-71		18
973	Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. 2013 , 24, 90-7		27
972	Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. 2013 , 72, 33-41; discussion 41		84
971	Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET. 2013 , 38, 381-4		9
970	Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution. 2013 , 53, 797-804		9
969	Peptide Vaccination Therapy Targeting Wilms' Tumor 1 (WT1) Gene Products against Malignant Gliomas. 2013 , 22, 619-624		
968	Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. 2013 , 110, 378-85		46
967	Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. 2013 , 6, 371-89		24
966	Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. 2013 , 8, e51951		62
965	Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. 2013 , 8, e56439		30

964	Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. 2013 , 8, e74242		46
963	Neuroimaging of primary central nervous system lymphoma in immunocompetent patients: comparison of recent and previous findings. 2013 , 80, 174-83		16
962	True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. 2013 , 14, 662-72		68
961	Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation. 2013 , 2013, 690585		39
960	Outcomes in newly diagnosed elderly glioblastoma patients after concomitant temozolomide administration and hypofractionated radiotherapy. <i>Cancers</i> , 2013 , 5, 1177-98	6.6	12
959	Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. 2014 , 6, 149-70		112
958	Clinical applications of choline PET/CT in brain tumors. 2015 , 21, 121-7		36
957	Radiosurgery for Glioblastoma. 2014 ,		
956	The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. 2014 , 9, e85102		28
955	Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. 2014 , 9, e113587		12
954	Identifying MRI markers associated with early response following laser ablation for neurological disorders: preliminary findings. 2014 , 9, e114293		12
953	The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. 2014 , 6, 373-87		27
952	Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. 2014 , 7, 485-90		41
951	Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. 2014 , 7, 1071-81		24
950	Antiangiogenic therapy for high-grade glioma. 2014 , CD008218		64
949	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. 2014 , 14, 439-52		63
948	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. 2014 , 15, 2047-61		16
947	Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. 2014 , 14, 729-40		34

946	A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. 2014 , 22, 1048-55		170
945	Impact of imaging measurements on response assessment in glioblastoma clinical trials. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii24-35	1	28
944	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii36-47	1	38
943	Pros and cons of current brain tumor imaging. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii2-11	1	43
942	Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. 2014 , 3, 407-19		22
941	Is a prospective trial necessary to suggest a clinical relevance?. <i>Neuro-Oncology</i> , 2014 , 16, 1295-6	1	2
940	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014 , 16, 567-78	1	110
939	Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma. 2014 , 5, S175-80		3
938	Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma. 2014 , 62, 42-7		24
937	Role of Amide Proton Transfer (APT)-MRI of Endogenous Proteins and Peptides in Brain Tumor Imaging. 2014 , 171-181		
936	Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. 2014 , 37, E4		42
935	The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. 2014 , 15, 11832-46		133
934	Is a picture really worth a 1000 words?. <i>Neuro-Oncology</i> , 2014 , 16, 1563-4	1	1
933	Application of PET-MRI in pseudo progression versus true progression in High Grade Gliomas: A new avenue!. 2014 , 5, 94-8		1
932	The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience. 2014 , 2014, 678191		2
931	Erratum: Highly cited works in neurosurgery. Part II: the citation classics. <i>Journal of Neurosurgery</i> , 2014 , 120, 1252-7	3,2	4
930	Strahlennekrose im Gehirn: Bildgebungsmerkmale und Abgrenzung zum Tumorrezidiv. 2014 , 02, 301-315		
929	Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas. 2014 , 32, 423-9		15

928	Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. <i>Radiology</i> , 2014 , 271, 200-10	20.5	121
927	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). <i>Neuro-Oncology</i> , 2014 , 16, 92-102	1	43
926	Glioblastoma: background, standard treatment paradigms, and supportive care considerations. 2014 , 42, 171-82		43
925	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , 2014 , 16, 829-40	1	134
924	Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFâ 2014 , 25, 1442-1447		59
923	Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. 2014 , 34, 633-42		2
922	Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. 2014 , 3, 592-602		46
921	Low-grade gliomas. 2014 , 19, 403-13		125
920	Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. 2014 , 61, 1792-7		18
919	Antiangiogenic therapy for glioblastoma: current status and future prospects. 2014 , 20, 5612-9		92
918	Texture Descriptors to distinguish Radiation Necrosis from Recurrent Brain Tumors on multi-parametric MRI. 2014 , 9035, 90352B		17
917	Measuring the pons: a non-invasive biomarker for pediatric diffuse intrinsic pontine glioma. 2014 , 3, 181-3		1
916	Imaging Biomarkers and Surrogate Endpoints in Oncology Clinical Trials. 2014 , 29-42		1
915	A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothed inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. 2014 , 20, 1900-9		172
914	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. 2014 , 3, 111		16
913	¹¹ C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas. 2014 , 39, 791-8		37
912	Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma. 2014 , 25, 611-3		1
911	A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. 2014 , 25, 717-22		15

910	Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation, and chemotherapy. 2014 , 36, 1047-55	17
909	Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients. <i>Frontiers in Neurology</i> , 2014 , 5, 220	4-1 27
908	[(11 C)-methionine positron emission tomography in the postoperative imaging and followup of patients with primary and recurrent gliomas. 2014 , 2014, 463152	7
907	Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. 2014 , 36, 451-7	35
906	The future of antiangiogenic treatment in glioblastoma. 2014 , 27, 675-82	14
905	Identifying MRI markers to evaluate early treatment related changes post laser ablation for cancer pain management. 2014 , 9036, 90362L	3
904	Multifunctional nanoparticles for brain tumor imaging and therapy. 2014 , 66, 42-57	226
903	Fractionated stereotactic radiotherapy using CyberKnife for the treatment of large brain metastases: a dose escalation study. 2014 , 26, 151-8	47
902	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. 2014 , 50, 260-6	26
901	Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). 2014 , 29, 131-138	3
900	Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. 2014 , 61, 95-101	61
899	Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study. 2014 , 190, 370-6	15
898	Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center. 2014 , 116, 261-6	14
897	Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. 2014 , 116, 325-31	22
896	A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. 2014 , 116, 315-24	30
895	Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study. 2014 , 116, 299-306	15
894	PNist: interactive volumetric measurements of plexiform neurofibromas in MRI scans. 2014 , 9, 683-93	5
893	Functional Imaging in Oncology. 2014 ,	1

892	Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014 , 16, 880-8	1	87
891	A randomized trial of bevacizumab for newly diagnosed glioblastoma. 2014 , 370, 699-708		1775
890	Impact of MRI head placement on glioma response assessment. 2014 , 118, 123-9		29
889	A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. 2014 , 117, 93-101		70
888	Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. 2014 , 19, 16-23		13
887	Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma. <i>Neuro-Oncology</i> , 2014 , 16, 1373-83	1	33
886	High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. 2014 , 61, 907-12		14
885	Medical Imaging in Clinical Trials. 2014 ,		14
884	Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria. 2014 , 21, 709-15		9
883	Update on anti-angiogenic treatment for malignant gliomas. 2014 , 16, 380		16
882	Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. 2014 , 3, 91-100		67
881	Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. 2014 , 32, 452-64		135
880	Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. <i>Neuro-Oncology</i> , 2014 , 16, 274-9	1	143
879	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. <i>Neuro-Oncology</i> , 2014 , 16, 719-27	1	53
878	Diagnosing relapse in children's brain tumors using metabolite profiles. <i>Neuro-Oncology</i> , 2014 , 16, 156-64		16
877	Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery. 2014 , 31, 832		10
876	Adult brain tumor imaging: state of the art. 2014 , 49, 39-52		18
875	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. 2014 , 61, 833-9		71

874	Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?. 2014 , 10, 1277-97		100
873	Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. 2014 , 20, 5023-31		70
872	Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme. 2014 , 35, 498-503		48
871	Phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. <i>Neuro-Oncology</i> , 2014 , 16, 1255-62	1	37
870	The evolving role of neurological imaging in neuro-oncology. 2014 , 119, 491-502		2
869	Facing the future of brain tumor clinical research. 2014 , 20, 5591-600		4
868	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. 2014 , 20, 6304-13		89
867	Patterns of presentation and failure in patients with gliomatosis cerebri treated with partial-brain radiation therapy. 2014 , 120, 2713-20		5
866	Does early identification of low-grade glioma growth impact outcome?. <i>Neuro-Oncology</i> , 2014 , 16, 1296	1	
865	3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. 2014 , 90, 181-9		35
864	Semiautomatic segmentation and follow-up of multicomponent low-grade tumors in longitudinal brain MRI studies. 2014 , 41, 052303		16
863	A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. <i>Journal of Neurosurgery</i> , 2014 , 121, 536-42	3.2	19
862	Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?. <i>Journal of Neurosurgery</i> , 2014 , 121, 818-26	3.2	10
861	Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. 2014 , 11, 566-84		46
860	Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. 2014 , 76, 98-115		44
859	Positron emission tomography-magnetic resonance imaging in the evaluation of brain tumors: current status and future prospects. 2014 , 49, 275-89		1
858	Defining a therapeutic window for the novel TGF- β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. 2014 , 77, 796-807		61
857	Clinical practice experience with NovoTTF-100A β system for glioblastoma: The Patient Registry Dataset (PRiDe). 2014 , 41 Suppl 6, S4-S13		84

856	Response patterns of recurrent glioblastomas treated with tumor-treating fields. 2014 , 41 Suppl 6, S14-24	48
855	The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival. 2014 , 31, 122	7
854	Multimodal magnetic resonance imaging evaluation of primary brain tumors. 2014 , 41, 478-495	10
853	Circulating glioma biomarkers. <i>Neuro-Oncology</i> , 2015 , 17, 343-60	1 52
852	[Comparison of different radio-chemotherapy-based treatments of primary nonresectable glioblastomas]. 2014 , 190, 855-6	
851	Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. 2014 , 119, 413-20	2
850	Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. 2014 , 37, 73-8	19
849	The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. 2014 , 118, 435-60	64
848	A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). 2014 , 118, 335-343	39
847	Intracranial ganglioglioma WHO I: results in a series of eight patients treated with stereotactic interstitial brachytherapy. 2014 , 118, 345-350	3
846	A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. 2014 , 119, 369-76	29
845	Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm. 2014 , 119, 387-95	11
844	Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. 2014 , 2, 4	30
843	Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. 2014 , 55, 115-32	20
842	Pseudo-progression after stereotactic radiotherapy of brain metastases: lesion analysis using MRI cine-loops. 2014 , 119, 437-43	10
841	Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: a single-centre experience. <i>Radiologia Medica</i> , 2014 , 119, 721-6	6.5 8
840	MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview. 2014 , 50, 896-913	42
839	Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. <i>Neuro-Oncology</i> , 2014 , 16, 1146-54	74

838	Advanced magnetic resonance imaging of the physical processes in human glioblastoma. 2014 , 74, 4622-4637	97
837	(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. 2014 , 55, 30-6	100
836	Imaging and histological characterization of a human brain xenograft in pig: the first induced glioma model in a large animal. 2014 , 221, 159-65	15
835	Neurological imaging of brain damages after radiotherapy and/or chemotherapy. 2014 , 41, 52-70	9
834	Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms. 2014 , 39, 1096-103	22
833	Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). 2014 , 29, 131-8	41
832	Quantitative tumor segmentation for evaluation of extent of glioblastoma resection to facilitate multisite clinical trials. 2014 , 7, 40-7	20
831	Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. <i>Neuro-Oncology</i> , 2014 , 16, 696-706	1 85
830	Quantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat model. <i>Neuro-Oncology</i> , 2014 , 16, 856-67	1 37
829	[RECIST and the radiologist]. 2014 , 56, 193-205	5
828	Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. 2014 , 54, 272-9	16
827	Role of MRI in primary brain tumor evaluation. 2014 , 12, 1561-8	14
826	Optic pathway gliomas in adults. 2014 , 74, 273-9; discussion 279-80	14
825	The comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkers. 2014 , 74, 88-98	8
824	ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. 2014 , 44, 1843-52	174
823	Corrigendum to "Clinical Practice Experience With Novo TTF-100A System for Glioblastoma: The Patient Registry Dataset (PRiDe)" 2015 , 42, e33-e43	2
822	Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. 2015 , 46, 1883-92	44
821	Procarbazine, lomustine and vincristine for recurrent high-grade glioma. 2015 ,	

820	Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor- β receptor I kinase inhibitor LY2157299 monohydrate. 2015 , 9, 2442-2448	6
819	Corrigendum to "Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields" Seminars in Oncology, Vol 41, No 5, Suppl 6, October 2014, pp S14-S24. 2015 , 42, e44-e55	
818	Approximation of head and neck cancer volumes in contrast enhanced CT. 2015 , 15, 16	18
817	Brain Tumor Clinical Trials: Perspective 2014. 2015 , 62 Suppl 1, 141-5	
816	Rapid-Steady-State-T1 signal modeling during contrast agent extravasation: toward tumor blood volume quantification without requiring the arterial input function. 2015 , 73, 1005-14	4
815	Tumor volumetric measurements in surgically inaccessible pediatric low-grade glioma. 2015 , 37, e31-6	4
814	Imaging of the Posttherapeutic Brain. 2015 , 24, 147-54	6
813	Multiparametric MRI as an early biomarker of individual therapy effects during concomitant treatment of brain tumours. 2015 , 28, 1163-73	7
812	Response Assessment and Magnetic Resonance Imaging Issues for Clinical Trials Involving High-Grade Gliomas. 2015 , 24, 127-36	15
811	. 2015 ,	2
810	EGFR and PTEN Gene Mutation Status in Glioblastoma Patients and their Prognostic Impact on Patient's Survival. 2015 , 06,	1
809	Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. 2015 , 30, 1597-603	6
808	Monitoring Reader Metrics in Blinded Independent Central Review of Oncology Studies. 2015 , 05,	
807	Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma. 2015 , 2015, 208076	15
806	The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping. 2015 , 2015, 641023	32
805	Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. 2015 , 128, 2751-8	9
804	Evidence-based neuro-oncology. 2015 , 143-152	
803	Malignant Glioma: Viewpoint "Chemotherapy. 2015 , 279-293	

802	Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. <i>Neuro-Oncology</i> , 2015 , 17, 1275-83	1	45
801	Calcification in high grade gliomas treated with bevacizumab. 2015 , 123, 283-8		6
800	A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. 2015 , 51, 522-532		121
799	Treatment outcome and patterns of failure in patients of non-pineal supratentorial primitive neuroectodermal tumor: review of literature and clinical experience form a regional cancer center in north India. 2015 , 157, 1251-66		9
798	Response assessment criteria for brain metastases: proposal from the RANO group. 2015 , 16, e270-8		472
797	BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. 2015 , 123, 259-66		14
796	Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. <i>Frontiers in Neurology</i> , 2015 , 6, 33	4.1	115
795	Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. 2015 , 94, e827		8
794	Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?. 2015 , 21, 337-42		7
793	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. 2015 , 314, 2535-43		696
792	Association of computerized texture features on MRI with early treatment response following laser ablation for neuropathic cancer pain: preliminary findings. 2015 , 2, 041008		1
791	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. 2015 , 8, 446-55		1
790	Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levels. 2015 , 41, 1332-41		36
789	A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. 2015 , 17, 743-50		10
788	Functional diffusion map: A biomarker of brain metastases response to treatment based on magnetic resonance image analysis. 2015 , 2015, 4282-5		5
787	Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. 2015 , 15, 506		100
786	Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. 2015 , 122, 135-43		25
785	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 266-73	1	45

784	Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. 2015 , 57, 11-20		51
783	Imaging biomarkers in primary brain tumours. 2015 , 42, 597-612		18
782	Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. 2015 , 122, 179-88		22
781	Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. <i>Neuro-Oncology</i> , 2015 , 17, 1148-56	1	84
780	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015 , 17, 854-61	1	257
779	Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. 2015 , 122, 329-38		16
778	Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology</i> , 2015 , 17, 868-81	1	91
777	Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. <i>Neuro-Oncology</i> , 2015 , 17, 784-800	1	42
776	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. 2015 , 84, 280-6		62
775	Immunophenotypic characterization of human glioblastoma stem cells: correlation with clinical outcome. 2015 , 116, 864-76		24
774	A Phase III study of radiation therapy (RT) and Oâ€benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. 2015 , 20, 650-8		39
773	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-â€ receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. 2015 , 33, 357-70		75
772	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. 2015 , 122, 111-9		14
771	Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. 2015 , 121, 557-63		32
770	Incorporation of biomarkers in phase II studies of recurrent glioblastoma. 2015 , 36, 153-62		3
769	Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome. 2015 , 157, 569-76		22
768	Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1197-213	2.2	123
767	Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. 2015 , 121, 627-34		30

766	Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. 2015 , 132, 1-8		14
765	Early Cerebral Blood Volume Changes Predict Progression After Convection-Enhanced Delivery of Topotecan for Recurrent Malignant Glioma. <i>World Neurosurgery</i> , 2015 , 84, 163-72	2.1	4
764	Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. <i>Neuro-Oncology</i> , 2015 , 17, 1609-19	1	41
763	Phase II study of PX-866 in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 1270-4	1	63
762	Advanced MR Imaging in Neuro-oncology. 2015 , 25 Suppl 2, 143-9		6
761	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. <i>Neuro-Oncology</i> , 2015 , 17, 1434-44	1	116
760	The influence of different classification standards of age groups on prognosis in high-grade hemispheric glioma patients. 2015 , 356, 148-52		14
759	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. 2015 , 21, 3610-8		53
758	[Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI]. 2015 , 86, 701-2, 704-9		
757	Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma. 2015 , 25, 172-80		5
756	Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. 2015 , 124, 215-21		19
755	Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis. 2015 , 72, 589-96		59
754	Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy. 2015 , 84, 1128-36		24
753	Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. 2015 , 122, 197-203		7
752	Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas. 2015 , 123, 151-60		6
751	Cardiac Safety of TGF- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. 2015 , 15, 309-23		60
750	Hypofractionated radiotherapy with concurrent temozolomide chemotherapy in patients with newly diagnosed RPA class V glioblastoma multiforme: promising early results. 2015 , 4, 19-27		1
749	Alpha shape theory for 3D visualization and volumetric measurement of brain tumor progression using magnetic resonance images. 2015 , 33, 787-803		15

748	Bevacizumab in high-grade gliomas: past, present, and future. 2015 , 15, 387-97		18
747	A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression. 2015 , 13, 12		12
746	The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. 2015 , 56, 88-92		47
745	A useful approach towards 3D representation of brain abnormality from its 2D MRI slides with a volumetric exclamation. 2015 ,		2
744	First-in-human dose study of the novel transforming growth factor- α receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. 2015 , 21, 553-60		166
743	Targeted Therapies for Solid Tumors. 2015 ,		1
742	Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists. 2015 , 35, 455-74		33
741	Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. 2015 , 91, 961-7		17
740	Use of bevacizumab in recurrent glioblastoma. 2015 , 4, 157-69		21
739	18F-fluoroethylcholine (18F-Cho) PET/MRI functional parameters in pediatric astrocytic brain tumors. 2015 , 40, e40-5		30
738	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. 2015 , 21, 2057-64		206
737	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015 , 17, 708-17	1	148
736	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , 2015 , 17, 992-8	1	83
735	Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. <i>Neuro-Oncology</i> , 2015 , 17, 924-34	1	52
734	Somatic mutations associated with MRI-derived volumetric features in glioblastoma. 2015 , 57, 1227-37		63
733	Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology. 2015 , 76, 298-302		4
732	Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors. 2015 , 191, 936-44		5
731	Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma. 2015 , 36, 1654-61		26

730	Volumetric glioma quantification: comparison of manual and semi-automatic tumor segmentation for the quantification of tumor growth. 2015 , 56, 1396-403		19
729	Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. 2015 , 7, 303ra138		171
728	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. 2015 , 16, e534-e542		425
727	Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. 2015 , 57, 1269-80		32
726	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. 2015 , 124, 413-20		20
725	Stereotactic LINAC radiosurgery for the treatment of typical intracranial meningiomas. Efficacy and safety after a follow-up of over 12 years. 2015 , 191, 921-7		12
724	: newly diagnosed glioblastoma. <i>Neuro-Oncology Practice</i> , 2015 , 2, 106-121	2.2	8
723	TGF- β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET. 2015 , 56, 1310-4		59
722	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015 , 17, 1188-98	1	224
721	Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3186-92	2.2	13
720	Brain Cancer: The New Frontiers. 2015 , 231-246		
719	Brain: Radiotherapy. 2015 , 45-59		
718	Experiences on two different stereotactic radiosurgery modalities of Gamma Knife and Cyberknife in treating brain metastases. 2015 , 157, 2003-9; discussion 2009		17
717	CNS Anticancer Drug Discovery and Development Conference White Paper. <i>Neuro-Oncology</i> , 2015 , 17 Suppl 6, vi1-26	1	29
716	Radiotherapy and temozolomide for anaplastic astrocytic gliomas. 2015 , 123, 129-34		6
715	Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas. 2015 , 157, 1757-64; discussion 1764		18
714	Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. 2015 , 70, 1299-312		33
713	Treatment outcome and patterns of failure in patients of pinealoblastoma: review of literature and clinical experience from a regional cancer centre in north India. 2015 , 31, 1291-304		7

712	Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. 2015 , 56, 1554-61	98
711	Bevacizumab in recurrent glioblastoma: open issues. 2015 , 11, 2655-2665	9
710	The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis. 2015 , 125, 339-49	18
709	Neuroimaging and genetic influence in treating brain neoplasms. 2015 , 25, 121-40	3
708	Quantifying unruptured giant intracranial aneurysms by measuring diameter and volume--a comparative analysis of 69 cases. 2015 , 157, 361-8; discussion 368	11
707	Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. 2015 , 121, 226-33	53
706	Medical management of brain tumors and the sequelae of treatment. <i>Neuro-Oncology</i> , 2015 , 17, 488-504	90
705	Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis. 2015 , 128, 60-9	32
704	Post progression survival in glioblastoma: where are we?. 2015 , 121, 399-404	8
703	Pseudoprogession of low-grade gliomas after radiotherapy. 2015 , 62, 35-9	22
702	Diffuse intrinsic pontine glioma: is MRI surveillance improved by region of interest volumetry?. 2015 , 45, 203-10	5
701	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015 , 17, 116-21	1 153
700	Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. 2015 , 121, 997-1007	61
699	Radiographic Detection and Advanced Imaging of Glioblastoma. 2016 , 81-103	
698	Molecular Imaging of Brain Tumours. 2016 ,	
697	¶Elemene treatment of glioblastoma: a single-center retrospective study. 2016 , 9, 7521-7526	16
696	Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases. 2016 , 5, 637-646	4
695	Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy. 2016 , 2, 223-228	45

694	2 Response assessmentsNeuro-oncologic response assessmentsResponse Assessment in Neuro-oncology. 2016 ,		
693	5 Perfusion imagingdynamic contrast-enhanced T1-weighted magnetic resonance imaging (DCE-MRI) perfusionDynamic contrast-enhanced T1-weighted magnetic resonance imaging (DCE-MRI) perfusionDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)Perfusion imaging. Dynamic Contrast-Enhanced T1-Weighted MRI (DCE-MRI) Perfusion. 2016 ,		1
692	8 Diffusion-Weighted Imaging for Gliomas. 2016 ,		
691	Re-Irradiation for Recurrent Gliomas: Treatment Outcomes and Prognostic Factors. 2016 , 57, 824-30		14
690	High-grade glioma management and response assessment-recent advances and current challenges. 2016 , 23, e383-91		25
689	Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?. <i>Frontiers in Neurology</i> , 2016 , 7, 120	4.1	32
688	MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. 2016 , 11, e0166096		7
687	Assessment of Glioma Response to Radiotherapy Using Multiple MRI Biomarkers with Manual and Semiautomated Segmentation Algorithms. 2016 , 26, 626-634		6
686	A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. 2016 , 138, 1538-44		4
685	Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study). 2016 , 61, 269-74		1
684	Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. 2016 , 27, 133-7		9
683	Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. 2016 , 20, 282-91		6
682	Comparison of visual metric and planimetry methods for brain tumor measurement in dogs. 2016 , 77, 471-7		3
681	Clinical Evaluation of a Fully-automatic Segmentation Method for Longitudinal Brain Tumor Volumetry. <i>Scientific Reports</i> , 2016 , 6, 23376	4.9	54
680	Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. 2016 , 14, 1345-1350		18
679	Usefulness of positron emission tomographic studies for gliomas. 2016 , 56, 396-408		11
678	Cancer Immunotherapy for Gliomas: Overview and Future Directions. 2016 , 56, 355-60		4
677	Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. 2016 , 16, 914		13

676 Brain Tumours. **2016**, 127-142

675 Neuroradiology of gliomas. 121-145

674 Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. *Neuro-Oncology*, **2017**, 19, 252-258 1 32673 Aspartate- α -hydroxylase (ASPH): A potential therapeutic target in human malignant gliomas. **2016**, 2, e00203 20672 Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?. **2016**, 128, 303-12 16671 Normalized Apparent Diffusion Coefficient in the Prognostication of Patients with Glioblastoma Multiforme. **2016**, 43, 127-33 3670 What Lessons Are Imparted From SWOG S9005 for Recurrent Meningioma?. *Journal of Clinical Oncology*, **2016**, 34, 1825-6 2.2 2669 AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. *Neuro-Oncology*, **2016**, 18, 1304-12 1 53668 Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. **2016**, 128, 463-71 11667 Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). **2016**, 22, 4797-4806 77666 Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro-Oncology*, **2016**, 18, 1199-208 1 398665 Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to ^{68}Ga -DOTATATE/-TOC uptake. *Neuro-Oncology*, **2016**, 18, 1538-1547 1 50664 CGCG clinical practice guidelines for the management of adult diffuse gliomas. **2016**, 375, 263-273 253663 Chemotherapy for intracranial ependymoma in adults. **2016**, 16, 287 17662 Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. **2016**, 130, 495-503 14661 Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. **2016**, 130, 591-599 20660 Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience. **2016**, 66, 9-16 14659 Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas. **2016**, 27, 269-276 11

658	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017 , 19, 750-761	1	47
657	Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor- β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 567-575	1	16
656	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. 2016 , 3, e388-97		93
655	Detecting tumor progression in glioma: current standards and new techniques. 2016 , 16, 1177-1188		14
654	TTFields Therapy. 2016 , 243-256		2
653	RANO Criteria. 2016 , 409-418		2
652	A longitudinal magnetic resonance elastography study of murine brain tumors following radiation therapy. 2016 , 61, 6121-31		20
651	Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. 2016 , 130, 193-201		14
650	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. 2016 , 23, 1073-82		13
649	Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. 2016 , 12, e23-9		19
648	Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. <i>Neuro-Oncology</i> , 2017 , 19, 242-251	1	59
647	Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. <i>Neuro-Oncology</i> , 2017 , 19, 430-439	1	15
646	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. 2016 , 129, 221-30		11
645	<i>Neuro-Oncology</i> . 2016 , 849-904		
644	Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. 2016 , 24, 705-718		16
643	Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies. 2016 , 58, 1027-1034		12
642	Iodine-125 brachytherapy as upfront and salvage treatment for brain metastases : A comparative analysis. 2016 , 192, 780-788		7
641	Stereotactic brachytherapy using iodine 125 seeds for the treatment of primary and recurrent anaplastic glioma WHO ^o III. 2016 , 130, 123-131		13

640	Suspected recurrence of brain metastases after focused high dose radiotherapy: can [F]FET- PET overcome diagnostic uncertainties?. 2016 , 11, 139	46
639	A Simple Automated Method for Detecting Recurrence in High-Grade Glioma. 2016 , 37, 2019-2025	6
638	Surgical resection of fourth ventricular ependymomas: case series and technical nuances. 2016 , 130, 341-349	15
637	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. 2016 , 8, 341ra75	123
636	Alternating Electric Fields Therapy in Oncology. 2016 ,	2
635	Clinical Efficacy of Tumor Treating Fields for Recurrent Glioblastoma. 2016 , 67-77	
634	Tumor Treating Fields in Clinical Practice with Emphasis on PRiDe Registry. 2016 , 79-92	1
633	Tumor Treating Fields Therapy for Newly Diagnosed Glioblastoma. 2016 , 93-102	
632	Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images. 2016 , 8, 47-59	9
631	Health-related quality of life in brain tumor patients: as an endpoint in clinical trials and its value in clinical care. 2016 , 1, 37-44	12
630	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. 2016 , 31, 99-105	8
629	Assessment of Brain Tumor Response: RANO and Its Offspring. 2016 , 17, 35	49
628	4 Perfusion imagingDynamic susceptibility contrast magnetic resonance perfusion (DSC-MRP)Perfusion Imaging: Dynamic Susceptibility Contrast Magnetic Resonance Perfusion. 2016 , ,	
627	Highlights from the Literature. <i>Neuro-Oncology</i> , 2016 , 18, 605-608	1 78
626	Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. 2016 , 18, 396-407	12
625	Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging. 2016 , 11, 2432-2436	28
624	A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. 2016 , 129, 281-8	57
623	Semi-Automated Volumetric and Morphological Assessment of Glioblastoma Resection with Fluorescence-Guided Surgery. 2016 , 18, 454-62	22

622	A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Muropeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. 2016 , 22, 4776-4785		89
621	Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. 2016 , 86, 2226-34		133
620	RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. 2016 , 62, 138-45		117
619	Use of Neuroimaging for Radiation Therapy Planning. 2016 , 231-241		
618	Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. 2016 , 667-680		
617	Pseudoprogression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation. 2016 , 681-695		
616	Neuroimaging. 2016 , 134, 27-50		6
615	A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. 2016 , 129, 139-46		29
614	Dogs are man's best friend: in sickness and in health. <i>Neuro-Oncology</i> , 2017 , 19, 312-322	1	18
613	Therapeutic options in recurrent glioblastoma--An update. 2016 , 99, 389-408		130
612	Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. 2016 , 126, 347-54		26
611	High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. 2016 , 126, 545-50		15
610	Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. 2016 , 126, 551-7		18
609	Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series. 2016 , 126, 1002-6		13
608	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1611-9	2.2	124
607	Glioblastoma. 2016 , 134, 381-97		160
606	Usefulness of PET Imaging to Guide Treatment Options in Gliomas. 2016 , 18, 4		13
605	Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. 2016 , 55, 418-22		10

604	Second surgery for recurrent glioblastoma: A concise overview of the current literature. 2016 , 142, 60-64		50
603	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016 , 18, 549-56	1	129
602	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016 , 34, 945-52	2.2	121
601	Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. <i>Neuro-Oncology Practice</i> , 2016 , 3, 59-67	2.2	15
600	Recurrent glioblastoma: who receives tumor specific treatment and how often?. 2016 , 128, 85-92		12
599	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016 , 18, 1137-45	1	88
598	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. 2016 , 22, 575-81		47
597	Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI. 2016 , 37, 28-36		86
596	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. <i>Neuro-Oncology</i> , 2016 , 18, 261-8	1	25
595	Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. 2016 , 126, 279-88		29
594	Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme. 2016 , 37, 23-29		14
593	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. <i>Neuro-Oncology Practice</i> , 2017 , 4, 15-23	2.2	5
592	Reliability of Semi-Automated Segmentations in Glioblastoma. 2017 , 27, 153-161		23
591	Prognostic value of post-treatment metabolic tumor volume from C-methionine PET/CT in recurrent malignant glioma. 2017 , 40, 223-229		17
590	Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients. 2017 , 25, 497-504		14
589	ACTC1 as an invasion and prognosis marker in glioma. <i>Journal of Neurosurgery</i> , 2017 , 126, 467-475	3.2	21
588	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. 2017 , 13, 386-394		76
587	Clinical efficacy and safety of surface imaging guided radiosurgery (SIG-RS) in the treatment of benign skull base tumors. 2017 , 132, 307-312		14

586	Clinical Relevance of Steroid Use in Neuro-Oncology. 2017 , 17, 5		28
585	Antiangiogenic Therapy for Malignant Gliomas. 2017 , 163-175		
584	Glioblastoma. 2017 , 265-288		1
583	New Directions in Anti-Angiogenic Therapy for Glioblastoma. <i>Neurotherapeutics</i> , 2017 , 14, 321-332	6.4	71
582	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. <i>Neurotherapeutics</i> , 2017 , 14, 307-320	6.4	158
581	A novel approach to segmentation and measurement of medical image using level set methods. 2017 , 39, 175-193		14
580	Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. 2017 , 131, 507-516		4
579	Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. 2017 , 111, 94-102		61
578	Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine. 2017 , 38, 908-914		22
577	Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. 2017 , 6, 185-193		27
576	Multimodal Magnetic Resonance Imaging of Treatment-Induced Changes to Diffuse Infiltrating Pontine Gliomas in Children and Correlation to Patient Progression-Free Survival. 2017 , 99, 476-485		17
575	Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial. <i>Neuro-Oncology</i> , 2017 , 19, 853-861	1	19
574	Extent of surgical resection and adjuvant temozolomide improves survival in pediatric GBM: a single center experience. 2017 , 33, 951-956		7
573	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. 2017 , 15, 104		65
572	Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?. 2017 , 99, 450-458		4
571	Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment. 2017 , 24, 1027-1035		3
570	Biopsy versus resection for the management of low-grade gliomas. 2017 , 4, CD009319		16
569	Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group. 2017 , 57, 17-27		6

568	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017 , 19, 625-635	1	87
567	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 1542-1552	1	78
566	Imaging Studies in Immunotherapy. 2017 , 149-179		1
565	An Update on the Approach to the Imaging of Brain Tumors. 2017 , 17, 53		10
564	The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. <i>Neuro-Oncology</i> , 2017 , 19, 1097-1108	1	37
563	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. 2017 , 133, 589-594		15
562	A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. 2017 , 64, e26621		9
561	Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations. <i>World Neurosurgery</i> , 2017 , 105, 895-905	2.1	17
560	Pseudoprogession, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. 2017 , 134, 495-504		95
559	Central nervous system gliomas. 2017 , 113, 213-234		84
558	Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. 2017 , 34, 62-77		58
557	Advanced MRI Techniques in the Monitoring of Treatment of Gliomas. 2017 , 19, 11		35
556	O and HO-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. 2017 , 31, 487-500.e8		193
555	Comparing available criteria for measuring brain metastasis response to immunotherapy. 2017 , 132, 479-485		22
554	Micro-Multileaf Collimator LINAC Radiosurgery for Vestibular Schwannomas. <i>World Neurosurgery</i> , 2017 ,	2.1	2
553	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. 2017 , 18, 682-694		336
552	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. 2017 , 264, 350-358		19
551	Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. 2017 , 131, 321-329		13

550	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. 2017 , 25, 2620-2634		130
549	Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. 2017 , 59, 1013-1020		11
548	Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy. <i>Scientific Reports</i> , 2017 , 7, 8508	4.9	14
547	Pseudoprogession after glioma therapy: an update. 2017 , 17, 1109-1115		32
546	Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?. 2017 , 135, 285-297		22
545	The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogession: A meta-analysis. 2017 , 96, e6333		18
544	Procarbazine, lomustine and vincristine for recurrent high-grade glioma. 2017 , 7, CD011773		16
543	Resisting RECIST-Uniformity Versus Clinical Validity. 2017 , 27, 1619-1627		1
542	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. 2017 , 390, 1645-1653		225
541	Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences. 2017 , 24, 1255-e70		6
540	O and HO-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. 2017 , 32, 268		74
539	Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors. 2017 , 24, 180-186		5
538	Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas. 2017 , 135, 443-452		21
537	Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis. 2017 , 7, e017387		22
536	Treatment Outcome in Patients with Primary Central Nervous System Germ Cell Tumour: Clinical Experience from a Regional Cancer Centre in North India. 2017 , 52, 240-249		3
535	Chemotherapy for Diffuse Low Grade Gliomas. 2017 , 535-577		
534	The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity. 2017 , 2, 391-397		12
533	Recurrent glioblastoma: a single-institution experience with reirradiation and temozolomide. 2017 , 6, 133-141		1

532	Cerebral toxoplasmosis requiring urgent brain biopsy. 2017 , 9, 59-61	4
531	Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. 2017 , 26, 43-53	23
530	Intra-rater variability in low-grade glioma segmentation. 2017 , 131, 393-402	23
529	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. 2017 , 131, 193-199	33
528	The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma. 2017 , 44, 373-381	36
527	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. 2017 , 131, 105-115	45
526	Evaluation of pseudoprogression in patients with glioblastoma. <i>Neuro-Oncology Practice</i> , 2017 , 4, 120-134	8
525	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. 2017 , 318, 2306-2316	875
524	Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study. 2017 , 103, 457-463	3
523	Modern Imaging in Neurooncology. 2017 , 01, E160-E170	
522	Treatment of Edema Formation in Oncology. 2017 , 477-495	
521	Computed Tomography and Magnetic Resonance Imaging Are Equivalent in Mensuration and Similarly Inaccurate in Grade and Type Predictability of Canine Intracranial Gliomas. 2017 , 4, 157	10
520	Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications. 2017 , 5, 1-9	39
519	Immunotherapy Clinical Trials in Neuro-Oncology. 2017 , 181-210	
518	Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. 2017 , 2017, 7064120	56
517	Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. <i>Diagnostics</i> , 2017 , 7,	3.8 29
516	Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma. 2017 , 12, e0176528	23
515	Detection of human cytomegalovirus in glioblastoma among Taiwanese subjects. 2017 , 12, e0179366	14

514	The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma. 2017 , 12, e0186430		10
513	Moderne Bildgebung in der Neuroonkologie. 2017 , 44, 489-500		2
512	Response Assessment in Neuro-Oncology Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2439-2449.2		168
511	NANO, a practical scale for neurologic assessments in patients with brain tumors?. <i>Neuro-Oncology</i> , 2017 , 19, 603-604	1	2
510	Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients. 2017 , 8, 53542-53551		15
509	The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas. 2017 , 5, 77-86		11
508	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3760-3773	2.2	59
507	Clinical trial endpoints for patients with gliomas. <i>Neuro-Oncology Practice</i> , 2017 , 4, 201-208	2.2	4
506	Advanced magnetic resonance imaging in the study of primary intracranial brain tumors in adults: a state of art review. 2017 , 2, 56-56		
505	Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System. 2018 , 15, 767-771		16
504	Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials. 2018 , 59, 261-271		17
503	Leptomeningeal enhancement on preoperative brain MRI in patients with glioblastoma and its clinical impact. 2018 , 14, e366-e373		4
502	Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature. 2018 , 11, 1756285617753597		3
501	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. 2018 , 100, 1146-1154		7
500	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. 2018 , 126, 135-144		12
499	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. 2018 , 139, 383-388		9
498	Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab. 2018 , 39, 1017-1024		11
497	Intraventricular urokinase to treat a blocked ventriculoperitoneal shunt in a glioblastoma patient with leptomeningeal spread. 2018 , 160, 1073-1077		3

496	Quantification of glioblastoma mass effect by lateral ventricle displacement. <i>Scientific Reports</i> , 2018 , 8, 2827	4.9	13
495	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 975-985	1	5
494	Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?. 2018 , 167, 6-10		8
493	Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. 2018 , 60, 427-436		8
492	Clinical characteristics associated with the intracranial dissemination of gliomas. 2018 , 166, 141-146		4
491	A novel prognostic six-CpG signature in glioblastomas. 2018 , 24, 167-177		19
490	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. <i>World Neurosurgery</i> , 2018 , 110, e727-e737	2.1	10
489	Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. 2018 , 137, 439-446		16
488	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. 2018 , 137, 583-591		15
487	Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. 2018 , 124, 1455-1463		29
486	Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis. 2018 , 48, 729		19
485	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018 , 20, 1162-1172	1	38
484	The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis. <i>World Neurosurgery</i> , 2018 , 115, 453-459.e3	2.1	43
483	Neuroimaging classification of progression patterns in glioblastoma: a systematic review. 2018 , 139, 77-88		6
482	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. 2018 , 45, 1626-1635		12
481	65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update. 2018 , 25, T159-T169		12
480	Imaging Criteria in Neuro-oncology. 2018 , 38, 24-31		13
479	Timing of re-irradiation in recurrent high-grade gliomas: a single institution study. 2018 , 138, 571-579		7

478	Comments on the review article «Cerebral radiation necrosis: Diagnostic challenge and clinical management». 2018 , 33, 275-276		
477	Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. 2018 , 41, 813-819		9
476	Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy. 2018 , 55, 1396-1404		5
475	Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. 2018 , 38, 1741-1753		13
474	Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma. 2018 , 83, 385-392		12
473	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. <i>Neuro-Oncology</i> , 2018 , 20, 457-471	1	22
472	Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). <i>Radiologia Medica</i> , 2018 , 123, 48-62	6.5	11
471	Neurologic Complications of Corticosteroids in Cancer Therapy. 2018 , 359-376		
470	Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide. <i>World Neurosurgery</i> , 2018 , 109, e662-e668	2.1	4
469	Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. 2018 , 20, 939-953		44
468	Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial. 2018 , 14, e359-e365		
467	Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model. 2018 , 136, 565-576		26
466	State of the Art Treatment and Surveillance Imaging of Glioblastomas. 2018 , 53, 23-36		7
465	Response Assessment in Treated Brain Tumors: The Fundamentals. 2018 , 53, 37-44		
464	Tumor-Treating Fields: A Fourth Modality in Cancer Treatment. 2018 , 24, 266-275		116
463	Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 239-253	1.4	37
462	Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1419-1427	2.2	298
461	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. 2018 , 97, e11254		7

460	Short Course versus Standard Course of Radiotherapy in Glioblastoma Multiforme. 2018 , 09,		1
459	Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. 2018 , 2018, 6828396		82
458	Brain tumour post-treatment imaging and treatment-related complications. 2018 , 9, 1057-1075		25
457	Low-Grade Gliomas. 2018 , 573-579.e1		1
456	Repeatability of dynamic contrast enhanced v parameter in healthy subjects and patients with brain tumors. 2018 , 140, 727-737		6
455	Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. 2018 , 36, 512-519		5
454	Identification of Glioma Pseudoprogression Based on Gabor Dictionary and Sparse Representation Model. 2018 , 16,		2
453	The Emerging Role of Amino Acid PET in Neuro-Oncology. 2018 , 5,		16
452	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. <i>Scientific Reports</i> , 2018 , 8, 14429	4.9	8
451	CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. 2018 , 194, 1171-1179		8
450	Comparative evaluation of a novel, moderately hypofractionated radiation protocol in 56 dogs with symptomatic intracranial neoplasia. 2018 , 32, 2013-2020		14
449	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018 , 10,	6.6	31
448	Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 272-280	1.4	12
447	Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. <i>World Neurosurgery</i> , 2018 , 120, e818-e854	2.1	7
446	Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?. 2018 , 140, 623-628		16
445	Letter to the Editor Regarding "Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer". <i>World Neurosurgery</i> , 2018 , 118, 397-398	2.1	0
444	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018 , 20, 897-906	1	26
443	Advances in the systemic treatment of melanoma brain metastases. 2018 , 29, 1509-1520		20

442	Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. 2018 , 39, 1008-1016		25
441	Earliest radiological progression in glioblastoma by multidisciplinary consensus review. 2018 , 139, 591-598		2
440	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018 , 20, 1383-1392	1	99
439	Clinical Trial Design and Implementation in Neuro-Oncology. 2018 , 105-112		
438	Historical and Conventional Chemotherapy Approaches for High-Grade Astrocytomas. 2018 , 399-409		
437	Chemotherapy of Adult Ependymoma. 2018 , 483-485		
436	Issues in Response Assessment of Brain Tumor Chemotherapy. 2018 , 715-727		1
435	Pseudo-Progression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation. 2018 , 729-746		1
434	Response Assessment in Neuro-oncology (RANO): An Update. 2018 , 747-759		1
433	Immunotherapy Response Assessment in Neuro-Oncology (iRANO). 2018 , 761-766		1
432	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. 2018 , 171, 637-648		22
431	Letter: Role of Tyrosine Kinase Inhibitors in Recurrent Meningiomas: Controversies and Promises. 2018 , 82, E181-E183		0
430	On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images. 2018 , 106, 199-208		19
429	Structured Reporting in Neuroradiology: Intracranial Tumors. <i>Frontiers in Neurology</i> , 2018 , 9, 32	4.1	12
428	Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. <i>Frontiers in Oncology</i> , 2018 , 8, 18	5.3	30
427	Highlighting the need for reliable clinical trials in glioblastoma. 2018 , 18, 1031-1040		10
426	Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. 2018 , 45, 2377-2386		31
425	Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas. 2018 , 20, 51-60		23

424	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. 2018 , 45, 2404-2412		13
423	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. 2018 , 14, 1063-1069		7
422	Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DTK ROG trial). 2018 , 18, 15		17
421	Preoperative Two-Dimensional Size of Glioblastoma is Associated with Patient Survival. <i>World Neurosurgery</i> , 2018 , 115, e448-e463	2.1	6
420	Comments on the review article «Cerebral radiation necrosis: Diagnostic challenge and clinical management». 2018 , 33, 275-276		
419	Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. <i>Neuro-Oncology</i> , 2019 , 21, 274-284	1	17
418	Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. 2019 , 85, 335-342		5
417	Evaluation of the extent of resection and detection of ischemic lesions with intraoperative MRI in glioma surgery: is intraoperative MRI superior to early postoperative MRI?. <i>Journal of Neurosurgery</i> , 2018 , 131, 209-216	3.2	11
416	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019 , 21, 26-36	1	54
415	Evaluation of a novel software application for magnetic resonance distortion correction in cranial stereotactic radiosurgery. 2019 , 44, 136-143		1
414	Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). 2019 , 144, 303-311		17
413	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. 2019 , 9, 5085-5104		19
412	Current status of PET imaging in neuro-oncology. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz010	0.9	51
411	PET biomarkers and probes for treatment response assessment in glioblastoma: a work in progress. 2019 , 7, 285-294		1
410	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. 2019 , 8, CNS32		1
409	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. 2019 , 144, 403-407		23
408	Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme. 2019 , 11, 215-220		1
407	Intraclass Correlations of Measured Magnetic Resonance Imaging Volumes of Laser Interstitial Thermal Therapy-Treated High-Grade Gliomas. 2019 , 51, 790-796		2

406	Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. 2019 , 57, 1199-1216		28
405	Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma. 2019 , 405, 116433		8
404	Biopsy Confirmed Glioma Recurrence Predicted by Multi-Modal Neuroimaging Metrics. 2019 , 8,		3
403	First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. 2019 , 25, 6590-6597		25
402	Conventional MRI radiomics in patients with suspected early- or pseudo-progression. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz019	0.9	10
401	Emerging Applications of Artificial Intelligence in Neuro-Oncology. <i>Radiology</i> , 2019 , 290, 607-618	20.5	87
400	Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. 2019 , 63, 272-280		5
399	and Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2019 , 10, 703		13
398	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. 2019 , 116, 190-198		11
397	Imaging of Central Nervous System Tumors. 2019 , 111-142		
396	Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. <i>Frontiers in Neurology</i> , 2019 , 10, 460	4.1	28
395	Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. 2019 , 84, 327-336		15
394	Extensive Pachymeningeal Dissemination of Glioblastoma Mimicking Chronic Subdural Hematoma: A Case Report. 2019 , 7, 39-43		3
393	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. 2019 , 11, 76		10
392	PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. 2019 , 7, 66		15
391	Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. <i>Neuro-Oncology Practice</i> , 2019 , 6, 364-374	2.2	10
390	Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma. <i>World Neurosurgery</i> , 2019 , 126, e1510-e1517	2.1	3
389	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. 2019 , 143, 447-455		5

388	Spinal Metastases of Supratentorial Glioblastoma with Primitive Neuronal Component. 2019 , 2, 100019		7
387	The Use of PET/CT in Radiotherapy Planning for Brain Tumours. 2019 , 131-143		
386	PET/CT in Brain Disorders. 2019 ,		1
385	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. 2019 , 8, CNS28		87
384	Neuro-oncology: Assessing Response in Paediatric Brain Tumours. 2019 , 171-196		
383	Tumor Response Assessment: RECIST and Beyond. 2019 , 157-169		1
382	Imaging in Pediatric Oncology. 2019 ,		2
381	Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy. <i>World Neurosurgery</i> , 2019 , 125, 93-100	2.1	4
380	Are we ready to describe response or progression to immunotherapy in lung cancer?. 2019 , 138, 112-119		5
379	Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. <i>Scientific Reports</i> , 2019 , 9, 5585	4.9	8
378	Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial. 2019 , 39, 5		22
377	Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries. 2019 ,		6
376	Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy. <i>Neuro-Oncology</i> , 2019 , 21, 686-695	1	11
375	Radiology reporting of low-grade glioma growth underestimates tumor expansion. 2019 , 161, 569-576		9
374	Specific growth rates calculated from CTs in patients with head and neck squamous cell carcinoma: a retrospective study performed in Austria. 2019 , 9, e025359		6
373	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 2019 ,		2
372	Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. 2019 , 40, 1132-1139		10
371	Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. <i>Frontiers in Oncology</i> , 2019 , 9, 1134	5.3	16

370	Interval brain imaging for adults with cerebral glioma. 2019 , 12, CD013137		8
369	Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGF β Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up. <i>Cancers</i> , 2019 , 11,	6.6	12
368	Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging. 2019 , 19, 76		7
367	What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?. 2019 , 24, 71-73		6
366	Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression. <i>Neuro-Oncology Practice</i> , 2019 , 6, 22-29	2.2	0
365	Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. 2019 , 130, 104-112		115
364	Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. 2019 , 107, 15-27		21
363	The Role of Standard and Advanced Imaging for the Management of Brain Malignancies From a Radiation Oncology Standpoint. 2019 , 85, 165-179		5
362	Effect of Dexmedetomidine Combined Anesthesia on Motor evoked Potentials During Brain Tumor Surgery. <i>World Neurosurgery</i> , 2019 , 123, e280-e287	2.1	7
361	Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools. 2019 , 92, 20180730		9
360	Institutional Implementation of a Structured Reporting System: Our Experience with the Brain Tumor Reporting and Data System. 2019 , 26, 974-980		15
359	Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , 2019 , 21, i44-i61	1	55
358	Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors. <i>World Neurosurgery</i> , 2019 , 121, e836-e842	2.1	3
357	The Response Evaluation Criteria in Solid Tumors (RECIST). 2019 , 501-511		5
356	The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma. 2019 , 84, 687-695		12
355	Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas. 2019 , 84, 190-197		27
354	Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma. 2020 , 98, 16-22		8
353	Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone. 2020 , 5, 53-61		10

352	Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis. 2020 , 61, 498-504		16
351	The correlation of fractional anisotropy parameters with Ki-67 index, and the clinical implication in grading of non-enhancing gliomas and neuronal-glioma tumors. 2020 , 65, 129-135		0
350	Machine learning and glioma imaging biomarkers. 2020 , 75, 20-32		31
349	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. 2020 , 38, 831-843		32
348	Glioma Imaging. 2020 ,		2
347	Atlas of Response to Immunotherapy. 2020 ,		
346	Therapy Response Imaging in Oncology. 2020 ,		
345	Imaging for Response Assessment in Radiation Oncology: Current and Emerging Techniques. 2020 , 34, 293-306		6
344	Imaging Gliomas After Treatment. 2020 ,		
343	Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. 2020 , 20, 137-146		1
342	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. 2020 , 146, 659-670		10
341	Volumetric segmentation of glioblastoma progression compared to bidimensional products and clinical radiological reports. 2020 , 162, 379-387		9
340	Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients. 2020 , 146, 157-162		5
339	Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa085	0.9	0
338	Robust Deep Learning-based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training. 2020 , 2, e190103		5
337	Assessment of Pre-operative Measurements of Tumor Size by MRI Methods as Survival Predictors in Wild Type IDH Glioblastoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1662	5.3	2
336	Metabolic Imaging of Brain Tumor Recurrence. 2020 , 215, 1199-1207		2
335	Estrogen hormone replacement therapy in incidental intracranial meningioma: a growth-rate analysis. <i>Scientific Reports</i> , 2020 , 10, 17960	4.9	2

334	Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. 2021 , 44, 1943-1955		3
333	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa124	0.9	1
332	Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology. 2020 , 26, 5388-5399		5
331	Diagnose und Therapie der Gliome des Erwachsenen. 2020 , 23, 65-75		
330	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. 2020 , 20, 785-795		13
329	Multi-Parametric Deep Learning Model for Prediction of Overall Survival after Postoperative Concurrent Chemoradiotherapy in Glioblastoma Patients. <i>Cancers</i> , 2020 , 12,	6.6	3
328	Early Treatment Response Assessment Using F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. 2021 , 62, 918-925		8
327	Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies. 2020 , 41, 866-873		1
326	Frequent Clinical and Radiological Progression of Optic Pathway/Hypothalamic Pilocytic Astrocytoma in Adolescents and Young Adults. 2020 , 60, 277-285		1
325	A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. 2020 , 38, 1784-1795		22
324	Anti-epidermal growth factor receptor therapy for glioblastoma in adults. 2020 , 5, CD013238		11
323	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. 2020 , 21, e317-e329		31
322	5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review. 2020 , 195, 105913		5
321	Two-staged gamma knife radiosurgery for treatment of numerous (>10) brain metastases. 2020 , 195, 105847		1
320	Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma. 2020 , 41, 1193-1200		5
319	On point in primary CNS lymphoma. 2020 , 38, 640-647		2
318	Exploring Predictors of Response to Dacomitinib in -Amplified Recurrent Glioblastoma. 2020 , 4,		9
317	Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma. 2020 , 52, 978-997		7

316	NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. 2020 , 126, 2821-2828		10
315	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 1505-1515	1	8
314	Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. 2020 , 126, 2625-2636		30
313	Early imaging marker of progressing glioblastoma: a window of opportunity. 2020 , 148, 629-640		2
312	Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. <i>Scientific Reports</i> , 2020 , 10, 9223	4-9	10
311	Survival after reoperation for recurrent glioblastoma. 2020 , 73, 118-124		6
310	Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series. 2020 , 47, 525-530		3
309	Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques. 2020 , 41, 10-20		31
308	Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. 2020 , 47, 1476-1485		6
307	Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. 2020 , 3, CD013261		15
306	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. 2020 , 7, 429-436		13
305	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial. <i>Neuro-Oncology</i> , 2020 , 22, 1862-1872	1	23
304	Predicting outcome in childhood diffuse midline gliomas using magnetic resonance imaging based texture analysis. 2021 , 48, 243-247		5
303	Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study). 2021 , 31, 2933-2943		6
302	Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns. 2021 , 23, 554-564		2
301	MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. 2021 , 27, 179-188		5
300	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021 , 23, 468-477	1	10
299	Nanomedicine: future therapy for brain cancers. 2021 , 37-74		0

298	Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. 2021 , 31, 103-120		9
297	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features. 2021 , 157, 103188		6
296	Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. <i>Neuro-Oncology</i> , 2021 , 23, 314-323 ¹		8
295	Perfusion CT and MR Imaging of the Brain. 2021 , 203-225		
294	Differentiating Radiation-Induced Necrosis from Tumor Progression After Stereotactic Radiosurgery for Brain Metastases, Using Evaluation of Blood Flow with Arterial Spin Labeling (ASL): The Importance of Setting a Baseline. 2021 , 128, 113-119		1
293	Resected WHO grade I meningioma and predictors of local control. 2021 , 152, 145-151		3
292	Evaluation and Assessment of the Radio-Peptide Treatment Efficacy. 2021 , 163-170		
291	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab028	0.9	4
290	Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab052	0.9	1
289	Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab029	0.9	1
288	A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab003	0.9	0
287	A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research. <i>Frontiers in Oncology</i> , 2021 , 11, 620070	5.3	3
286	A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution. <i>Frontiers in Oncology</i> , 2021 , 11, 597587	5.3	2
285	Benefit of Static FET PET in Pretreated Pediatric Brain Tumor Patients with Equivocal Conventional MRI Results. 2021 , 233, 127-134		1
284	Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis. 2021 , 21, 167		10
283	Gamma Knife Stereotactic Radiosurgery for the treatment of chordomas and chondrosarcomas. 2021 , 163, 1003-1011		4
282	Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. 2021 , 27, 261.e1-261.e7		
281	Assessment of therapy response to Regorafenib by 18F-DOPA-PET/CT in patients with recurrent high-grade gliomas: a case series. 2021 , 9, 265-274		0

280	Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers. 2021 , 159, 103230		9
279	Circulating Tumor Cells for Glioma. <i>Frontiers in Oncology</i> , 2021 , 11, 607150	5.3	4
278	Treatment of Embryonal Tumours with Multilayered Rosettes with Carboplatin/Etoposide Induction and High-dose Chemotherapy within the Prospective P-HIT Trial. <i>Neuro-Oncology</i> , 2021 ,	1	0
277	Comparison of Measurement Techniques and Response Criteria for MR Imaging Follow-up in Adult Primary Central Nervous System Lymphoma. 2021 , 42, 1415-1420		1
276	Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences. <i>Cancers</i> , 2021 , 13,	6.6	8
275	Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. 2021 , 216, 1099-1111		1
274	Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. <i>Neuro-Oncology</i> , 2021 ,	1	6
273	European Society for Paediatric Oncology (SIOPE) MRI guidelines for imaging patients with central nervous system tumours. 2021 , 37, 2497-2508		6
272	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. 2021 , 62, 2400-2407		1
271	Imaging Surveillance of Gliomas: Role of Basic and Advanced Imaging Techniques. 2021 , 59, 395-407		
270	Clinical Review of Computed Tomography and MR Perfusion Imaging in Neuro-Oncology. 2021 , 59, 323-334		1
269	Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab073	0.9	0
268	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. 2021 , 22, 813-823		24
267	Imaging biomarkers for evaluating tumor response: RECIST and beyond. 2021 , 9, 52		10
266	56-jährige Patientin mit rasch progredientem, atraumatischem Konus-Kauda-Syndrom. 2021 , 4, 393-396		
265	Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. 2021 , 154, 187-196		1
264	Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma. 2021 , 1		5
263	Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine. 2021 , 27, 410-415		0

262	AIM and Brain Tumors. 2021 , 1-16	
261	Novel Magnetic Resonance Imaging and Positron Emission Tomography in the RT Planning and Assessment of Response of Malignant Gliomas. 2021 , 1031-1048	
260	Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. 2021 , 10, 1902071	2
259	Grade 2 Gliomas. 2021 , 173-191	
258	Stereotactic radiosurgery for treating meningiomas eligible for complete resection. 2021 , 16, 22	1
257	Anti-angiogenic therapy for high-grade glioma. 2018 , 11, CD008218	51
256	Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. 2006 , 9, 561-8	17
255	Applications in Malignant Brain Tumors. 2006 , 165-186	1
254	Principles of Clinical Trial Design and Response Assessment. 2011 , 85-102	0
253	Semi-automatic Brain Tumor Segmentation by Drawing Long Axes on Multi-plane Reformat. 2019 , 441-455	1
252	Nuclear Medicine Imaging of CNS: Basis and Clinical Applications. 2015 , 595-670	0
251	New Individualized and Dynamic Therapeutic Strategies in DLGG. 2017 , 609-624	1
250	Aggressive oligodendroglioma: a chemosensitive tumor. 1994 , 135, 127-33	14
249	Angiogenesis and Brain Tumors. 2011 , 1151-1171	1
248	Brain Tumor Outcome Studies. 2011 , 1243-1253	1
247	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. 2010 , 2010, 118-119	3
246	Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. 1997 , 20, 226-9	53
245	Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. 1997 , 20, 364-7	35

244	Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. 1998 , 21, 338-40	15
243	Toxicity and Efficacy of Carboplatin and Etoposide in Conjunction with Disruption of the Blood-Brain Tumor Barrier in the Treatment of Intracranial Neoplasms. 1995 , 37, 17??28	6
242	Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. 2021 , 44, 49-52	2
241	Days Gained Response Discriminates Treatment Response in Patients with Recurrent Glioblastoma Receiving Bevacizumab-based Therapies.	1
240	Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre. 2018 , 46, 883-894	3
239	High-grade Gliomas. 2017 , 23, 1548-1563	29
238	Aggressive oligodendroglioma: a chemosensitive tumor. 1992 , 31, 78-82	93
237	Diagnosis and treatment in neuro-oncology: an oncological perspective. 2011 , 84 Spec No 2, S82-9	37
236	O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. 2011 , 6, e17156	80
235	Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. 2012 , 7, e33449	96
234	DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. 2012 , 7, e35857	27
233	Distribution and radiosensitizing effect of cholesterol-coupled Dbait molecule in rat model of glioblastoma. 2012 , 7, e40567	16
232	Intracranial ependymoma: long-term results in a series of 21 patients treated with stereotactic (125)iodine brachytherapy. 2012 , 7, e47266	4
231	Pituitary adenoma volumetry with 3D Slicer. 2012 , 7, e51788	50
230	Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. 2013 , 8, e63682	115
229	Chemoirradiation for glioblastoma multiforme: the national cancer institute experience. 2013 , 8, e70745	11
228	Multi-modal glioblastoma segmentation: man versus machine. 2014 , 9, e96873	92
227	Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma. 2014 , 9, e108414	23

226	Stereotactic LINAC-Radiosurgery for Glomus Jugulare Tumors: A Long-Term Follow-Up of 27 Patients. 2015 , 10, e0129057	27
225	Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors. 2016 , 11, e0155315	11
224	Glioblastoma Segmentation: Comparison of Three Different Software Packages. 2016 , 11, e0164891	22
223	Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment. 2016 , 11, e0167917	19
222	Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. 2017 , 12, e0173112	12
221	PET Imaging in Glioblastoma: Use in Clinical Practice. 155-174	11
220	Development of a Multiparametric Voxel-Based Magnetic Resonance Imaging Biomarker for Early Cancer Therapeutic Response Assessment. 2015 , 1, 44-52	17
219	Semiautomated Workflow for Clinically Streamlined Glioma Parametric Response Mapping. 2016 , 2, 267-275	8
218	Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival. 2017 , 3, 131-137	8
217	The Longitudinal Imaging Tracker (BRICS-LIT):A Cloud Platform for Monitoring Treatment Response in Glioblastoma Patients. 2020 , 6, 93-100	5
216	Radiogenomics of lower-grade gliomas: a radiomic signature as a biological surrogate for survival prediction. 2018 , 10, 2884-2899	18
215	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. 2016 , 7, 80091-80100	2
214	Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. 2017 , 8, 7003-7013	50
213	Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. 2017 , 8, 13223-13239	20
212	Biological basis and clinical study of glycogen synthase kinase-3 β -targeted therapy by drug repositioning for glioblastoma. 2017 , 8, 22811-22824	26
211	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. 2017 , 8, 55575-55581	9
210	End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. 2014 , 5, 12769-87	22
209	Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. 2016 , 7, 25783-90	9

208	Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review. 2019 , 15, 933-947		2
207	Choline-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage. 2019 , 12, 88-92		6
206	Combined stereotactic split-course fractionated gamma knife radiosurgery and conventional radiation therapy for unfavorable gliomas: a phase I study. <i>Journal of Neurosurgery</i> , 2000 , 93, 37-41	3.2	12
205	Efficacy of gamma knife radiosurgery for nonfunctioning pituitary adenomas: a quantitative follow up with magnetic resonance imaging-based volumetric analysis. <i>Journal of Neurosurgery</i> , 2002 , 97, 429-432	2.3	57
204	The clinical features of spinal leptomeningeal dissemination from malignant gliomas. 2011 , 49, 334-8		22
203	Chemotherapy for malignant gliomas based on histoculture drug response assay : a pilot study. 2011 , 50, 426-33		7
202	Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients. 2012 , 52, 92-7		5
201	Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. 2013 , 54, 489-95		10
200	Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group. 2014 , 55, 5-11		18
199	Upfront Stereotactic Radiosurgery for Pineal Parenchymal Tumors in Adults. 2015 , 58, 334-40		8
198	Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma. 2015 , 58, 426-31		10
197	The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas. 2017 , 60, 15-20		6
196	Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. <i>Cancers</i> , 2020 , 13,	6.6	10
195	Post-treatment imaging of high-grade gliomas. 2015 , 25, 102-8		9
194	Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors. 2015 , 36, 99-104		12
193	Clinical profile and outcomes in brainstem glioma: An institutional experience. 2015 , 10, 298-302		6
192	Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma. 2012 , 3, 137		10
191	Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients. 2016 , 7, 92		13

190	Recurrent Glioblastoma: Where we stand. 2015 , 4, 163-73	62
189	Outcomes of adult medulloblastoma treated with a multimodality approach: A tertiary cancer center experience. 2015 , 4, 174-8	3
188	Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and Genes. 2018 , 13, 46-52	7
187	Glioma characterization based on magnetic resonance imaging: Challenge overview and future perspective. 2020 , 3, 61	1
186	Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide. 2019 , 56, 59-64	1
185	Prognostic Factors and Survival Outcomes of Intracranial Ependymoma Treated with Multimodality Approach. 2017 , 38, 420-426	2
184	Treatment in Elderly Glioblastoma Patients: General Reduction of Standard Therapy Should Be Avoided. Prognostic Value of MGMT Is Questionable. 2013 , 04, 1217-1223	2
183	Magnetic Resonance Perfusion Imaging in the Diagnosis of High-Grade Glioma Progression and Treatment-Related Changes: A Systematic Review. 2018 , 08, 282-305	4
182	Objective response rate assessment in oncology: Current situation and future expectations. 2020 , 11, 53-73	16
181	Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study. 2014 , 68, 140-3	13
180	Efficacy of high dose radiotherapy in post-operative treatment of glioblastoma multiforme--a single institution report. 2014 , 15, 2793-6	6
179	Prognostic factors influencing clinical outcomes of malignant glioblastoma multiforme: clinical, immunophenotypic, and fluorescence in situ hybridization findings for 1p19q in 816 chinese cases. 2015 , 16, 971-7	10
178	Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme. 2017 , 11, XC04-XC08	12
177	Response Assessment of Bevacizumab for Treatment of Malignant Glioma by Neuroimaging. 2016 , 25, 912-921	1
176	Central Nervous System Malignancies. 2021 , 731-754	
175	Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab141	0.9
174	The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. 2021 , 1	1
173	Chemotherapy in Adult CNS Tumors. 2003 , 437-448	

172 High-dose chemotherapy of cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation for metastatic breast cancer patients: a 6-year follow-up result. **2005**, 37, 24-30 o

171 Cytotoxic Chemotherapy for Diffuse Gliomas. **2007**, 153-170

170 Neuroimaging Issues in Assessing Response to Brain Tumor Therapy. **2008**, 504-514

169 Malignant Glioma: Chemotherapy Perspective. **2008**, 223-231

168 Treatment of Malignant Gliomas with Antisense Oligonucleotides. **2009**, 383-405

167 Tumori cerebrali. **2009**, 297-314

166 General Care of Patients with Cancer Involving the Central Nervous System. **2010**, 771-781

165 Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma. **2010**, 19, 758-766

164 High Grade Astrocytomas. 506-509

163 Glial Brain Tumors: Antiangiogenic Therapy. **2011**, 109-119

162 Early Clinical Trials with Cytotoxic Agents. **2011**, 335-345

161 Malignant Glioma Patients: Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, Bevacizumab. **2011**, 277-290

160 Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan. **2011**, 289-299

159 Recurrent Oligodendroglioma: Treatment with Bevacizumab. **2012**, 255-265

158 Post Chemotherapy Morphologic MR Imaging. **2012**, 41-44

157 Hirntumoren. **2012**, 573-584

156 Malignant Gliomas in Adulthood. 61-75

155 Chemotherapy for Diffuse Low-Grade Gliomas. **2013**, 401-422

- 154 Update on Glioma Treatments in the United States. **2013**, 22, 590-596
- 153 Introduction: From the Inhibition of Dogmas to the Concept of Personalized Management in Diffuse Low-Grade Gliomas. **2013**, 1-5
- 152 Toward the Definition of New Endpoints. **2013**, 457-462
- 151 Brain Metastases: Treatment with Stereotactic Iodine-125 Brachytherapy. **2014**, 173-186
- 150 MR Perfusion Imaging: ASL, T2*-Weighted DSC, and T1-Weighted DCE Methods. **2014**, 3-25
- 149 Medical Image Computing for Oncology: Review and Clinical Examples. **2014**, 97-124
- 148 Imaging Review Charters and Operational Considerations. **2014**, 65-82
- 147 MR Imaging Evaluation of Posttreatment Changes in Brain Neoplasms. **2014**, 603-640
- 146 Neuroimaging in Clinical Trials. **2014**, 197-235
- 145 Recent Advance and Updates in Chemotherapy for Glioma. **2014**, 23, 547-558
- 144 Phase II trial with BCNU Plus β B-Interferon in patients with recurrent high-grade gliomas. **1994**, 599-603
- 143 Concurrent radiochemotherapy in high-grade glioma. **1994**, 616-619
- 142 Non-Curative Radiotherapy for Neurological Cancer. **1998**, 159-172
- 141 Carboplatin and etoposide for recurrent malignant glioma: one department's experience. **1998**, 21, 215-6
- 140 Macdonald criteria for glioblastoma.
- 139 Glioma treatment response assessment in clinical trials.
- 138 Evaluation of Response in Malignant Tumors Treated with Targeted Agents. **2015**, 43-55
- 137 Hirntumoren. **2015**, 609-619

136	[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients]. 2016 , 80, 5-14	3
135	Lessons Learned. 2016 , 279-290	0
134	Recurrent Glioblastoma. 2016 , 151-165	
133	Pseudo-Progression in Breast Cancer Brain Metastasis after Initiating Therapy with Ado-Trastuzumab Emtansine. 2016 , 5,	
132	Re-evaluating the Efficacy and Toxicity of Procarbazine, Lomustine and Vincristine (PCV) in Relapsed Glioblastoma in the Concurrent/Adjuvant Temozolamide Era. 2016 , 6,	
131	Introduction: From the Inhibition of Dogmas to the Concept of Personalized Management in Patients with Diffuse Low-Grade Gliomas. 2017 , 1-9	
130	Surgery for Diffuse Low-Grade Gliomas (DLGG) Oncological Outcomes. 2017 , 469-495	
129	3.0T Imaging of Brain Gliomas. 2017 , 271-319	
128	Combined Salvage Therapies for Recurrent Glioblastoma Multiforme: Treatment Options in Multifocal and Multicentric Patterns of Recurrence. 2017 , 7,	1
127	Quantitation of brain tumour microstructure response to Temozolomide therapy using non-invasive VERDICT MRI.	1
126	CyberKnife Radiosurgery in Recurrent Brain Metastases: Do the Benefits Outweigh the Risks?. 2018 , 10, e3741	1
125	3D Conformal Re-Irradiation with Temozolamide for Recurrent Glioblastoma: A Prospective Cohort Study. 2019 , 10, 619-631	
124	An Update on Machine Learning in Neuro-Oncology Diagnostics. 2019 , 37-44	1
123	Tumor Progression&Pseudoprogression. 2019 , 2119-2138	
122	Modern operative nuances for the management of eloquent high-grade gliomas. 2019 , 63, 135-161	0
121	Parametric Response Map (PRM) Analysis Improves Response Assessment in Gliomas. 2020 , 109-126	
120	Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology.	1
119	Immunotherapy and Gliomas. 2020 , 251-265	

- 118 Indications and Limitations of Conventional Imaging âCurrent Clinical Practice in the Context of Standard Therapy. **2020**, 1-15 0
- 117 Evolution of Response Criteria in Immunotherapy. **2020**, 7-11
- 116 Clinical Trials: Endpoints and Outcome Assessment. **2020**, 407-421
- 115 Postchemotherapy Morphological MR Imaging. **2020**, 55-57
- 114 Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. **2020**, 21, 471-482 1
- 113 Magnetic Resonance Imaging for Quantification of Brain Vascular Perfusion. **2021**, 289-321
- 112 [Pseudoprogression of intracranial pilocytic astrocytomas and other low-grade gliomas. Literature review and case report]. **2020**, 84, 105-111
- 111 Salvage Irradiation for Patients with Recurrent Brain Metastases. **2020**, 371-378
- 110 Response Evaluation and Follow-Up by Imaging in Brain Tumours. **2020**, 381-404
- 109 Chemotherapy for Brain Tumors. **2021**, 357-383
- 108 Diagnostic accuracy of magnetic resonance imaging in detection of intra-axial gliomas. **2021**, 37, 125-130 1
- 107 When and How to Use Imaging in Brain Tumors, Protocols. **2020**, 15-28
- 106 Evolution of Clinical Trial Imaging and Co-clinical Imaging. **2020**, 239-253
- 105 Surgery for Recurrent Glioblastoma.
- 104 Current Status of the Use of Machine Learning and Magnetic Resonance Imaging in the Field of Neuro-Radiomics. **2020**, 1-11
- 103 Machine Learning and Glioblastoma: Treatment Response Monitoring Biomarkers in 2021. **2020**, 212-228 2
- 102 Radiation dose response of neurologic symptoms during conformal radiotherapy for diffuse intrinsic pontine glioma. **2020**, 147, 195-203 1
- 101 âEarly Imaging Marker of Progressive Glioblastoma: a window of opportunityâ

100	Radiation Necrosis in Intracranial Lesions. 2020 , 12, e7603	1
99	The value of intraoperative MRI in recurrent intracranial tumor surgery. <i>Journal of Neurosurgery</i> , 2021 , 135, 524-531	3,2
98	G. 2005 , 479-516	
97	General Care of Patients with Cancer Involving the Central Nervous System. 2006 , 687-696	
96	Oligodendroglioma. 2006 , 139-144	0
95	Detection of Proliferation in Gliomas by Positron Emission Tomography Imaging. 2006 , 419-432	
94	General Considerations. 2007 , 199-211	
93	Chemotherapy. 2007 , 267-282	
92	Nuclear Imaging of Gliomas. 2007 , 161-186	1
91	Tumoren des Nervensystems. 458-487	
90	Hirntumoren. 2008 , 577-588	
89	Phase II study of salvage therapy with high-dose tamoxifen and oral etoposide for recurrent malignant glioma. 2004 , 1, 53-60	
88	Neuro-oncology tracers: an already limited supply impacted by the pandemic?. 2020 , 41, 1223-1225	
87	Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma. 2015 , 5, 835-45	5
86	Practical guidelines for the treatment of malignant gliomas. 1998 , 168, 114-20	49
85	Role of bevacizumab therapy in the management of glioblastoma. 2010 , 2, 97-104	15
84	Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. 2011 , 9, Doc11	8
83	Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma. 2013 , 25, 206-11	4

82	The basics of diffusion and perfusion imaging in brain tumors. 2014 , 43, 22-29		13
81	Stereotactic radiosurgery and radiotherapy for meningiomas: biomarker predictors of patient outcome and response to therapy. 2012 , 2, 41-50		2
80	Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. 2014 , 34, 1939-45		19
79	Determining normal tissue dose in intracranial stereotactic radiosurgery: A diameter-based predictive nomogram. 2020 , 7, 67-75		
78	[Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases]. 2021 , 24, 124-130		
77	Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. 2000 , 21, 881-90		92
76	Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?. 2005 , 26, 770-6		87
75	Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. 2000 , 21, 471-8		37
74	Comparison of response assessment in veterinary neuro-oncology and two volumetric neuroimaging methods to assess therapeutic brain tumour responses in veterinary patients. 2021 ,		0
73	Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. 2021 , 155, 307-317		1
72	Treatment Response. 2022 , 589-596		
71	Delayed FDG PET Provides Superior Glioblastoma Conspicuity Compared to Conventional Image Timing. <i>Frontiers in Neurology</i> , 2021 , 12, 740280	4.1	0
70	F18-FET PET in pediatric brain tumors: integrative analysis of image derived parameters and clinico-pathological data. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 ,	1.4	1
69	Imaging Biomarkers of Glioblastoma Treatment Response: A Systematic Review and Meta-Analysis of Recent Machine Learning Studies.. <i>Frontiers in Oncology</i> , 2022 , 12, 799662	5.3	1
68	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study.. <i>Cancers</i> , 2022 , 14,	6.6	0
67	A comprehensive update to DC therapy for glioma; a systematic review and meta-analysis.. <i>Expert Review of Vaccines</i> , 2022 ,	5.2	0
66	Nuevos quimioterápicos en Neurooncología. 2003 , 5, 3-14		
65	Methoden klinischer Prüfung in der Onkologie. <i>Springer Reference Medizin</i> , 2021 , 1-53		0

64 AIM and Brain Tumors. **2022**, 1717-1732

63 Outcomes of Gamma Knife radiosurgery for skull base chondrosarcomas: a multi-institutional retrospective study.. *Journal of Neurosurgery*, **2022**, 1-8 3.2

62 Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives.. *Metabolites*, **2022**, 12, 5.6

61 [18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab. *Neuro-Oncology Practice*, 2.2 0

60 Sporadic Vestibular Schwannoma Size and Location Do not Correlate With the Severity of Hearing Loss at Initial Presentation.. *Frontiers in Oncology*, **2022**, 12, 836504 5.3 1

59 The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.. *Neuro-Oncology Advances*, **2022**, 4, vdac032 0.9

58 MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.. *Cancers*, **2022**, 14, 6.6 1

57 Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.. *Frontiers in Immunology*, **2022**, 13, 852811 8.4 2

56 High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.. *Frontiers in Oncology*, **2022**, 12, 810263 5.3 1

55 Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy.. *Neoplasia*, **2022**, 26, 100779 6.4 0

54 RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).. *Bioengineered*, **2021**, 12, 11768-11781 5.7 2

53 The Need for Medical Artificial Intelligence That Incorporates Prior Images.. *Radiology*, **2022**, 212830 20.5 0

52 Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions. **2022**, 2, 0

51 Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.. *Neuro-Oncology*, **2022**, 1 0

50 Image_1.tif. **2019**,

49 Image_2.tif. **2019**,

48 Table_1.docx. **2019**,

47 The Extent of Resection in Gliomas-Evidence-Based Recommendations on Methodological Aspects of Research Design.. *World Neurosurgery*, **2022**, 161, 382-395.e3 2.1 0

46	The role of PET in the management of brain tumors. 8-20		1
45	The basics of diffusion and perfusion imaging in brain tumors. 22-29		12
44	Updates in IDH-Wildtype Glioblastoma. <i>Neurotherapeutics</i> ,	6.4	1
43	Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma. <i>Radiologia Medica</i> ,	6.5	0
42	Standard clinical approaches and emerging modalities for glioblastoma imaging. <i>Neuro-Oncology Advances</i> ,	0.9	
41	Dynamic 18F-FET PET/CT to differentiate recurrent primary brain tumor and brain metastases from radiation necrosis after single-session robotic radiosurgery. <i>Cancer Treatment and Research Communications</i> , 2022 , 100583	2	
40	Ellipsoid calculations versus manual tumor delineations for glioblastoma tumor volume evaluation. <i>Scientific Reports</i> , 2022 , 12,	4.9	
39	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> ,	2.2	1
38	Central Nervous System. 2022 , 445-524		
37	Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging. 2,		1
36	Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature. <i>Diagnostics</i> , 2022 , 12, 1666	3.8	1
35	Response assessment in neuro-oncology criteria. 2022 , 491-499		
34	Tumour treating fields. 2022 , 269-283		
33	Basic premises: searching for new targets and strategies in diffuse gliomas.		0
32	Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma. 2022 , 14, 3771		2
31	Use of neuro-imaging for radiation therapy planning. 2022 , 257-267		0
30	Neuroimaging issues in assessing glioma response to brain tumour therapy. 2022 , 809-819		0
29	Pseudo-progression in neuro-oncology. 2022 , 821-839		0

28	Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case. 2022 , 4,	0
27	Intracranial meningiomas: clinical, intrascopic and pathomorphological causes of recurrence (literature review). 2022 , 21, 110-123	0
26	Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL). 2022 , 14, 4604	0
25	Histologic Findings at Time of Repeat Resection Predicts Survival in Patients with Glioblastoma. 2022 ,	0
24	Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.	0
23	Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. 2022 , 11, 5961	0
22	NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.	2
21	Can Extended Chemotherapy Improve Glioblastoma Outcomes? A Retrospective Analysis of Survival in Real-World Patients. 2022 , 12, 1670	0
20	Meningeosis Neoplastica in Patients with Glioblastoma: Analysis of 36 Cases. 2022 ,	0
19	Mapping glioma heterogeneity using multiparametric 18F-choline PET/MRI in childhood and teenage-young adults. Publish Ahead of Print,	0
18	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma.	7
17	The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation. 2022 , 9,	0
16	The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review. 2023 , 15, 483	0
15	ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449.	0
14	Salvage Chemotherapy in Progressive High-grade Astrocytoma. 2007 , 36, 343-346	1
13	Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625. 13,	0
12	Computational imaging applications in brain and breast cancer. 2023 , 29-45	0
11	Verlängerung des Gesamtüberlebens durch die Impfung von autologen tumorlysatbeladenen dendritischen Zellen (DCVax-L) bei Patienten mit neu diagnostiziertem und rezidivierendem Glioblastom.	0

10	Eighteen yearsâ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. 12,	0
9	MMP-9 as Prognostic Marker for Brain Tumours: A Comparative Study on Serum-Derived Small Extracellular Vesicles. 2023 , 15, 712	0
8	MRI Response Assessment in Patients with Glioblastoma Treated with Dendritic Cell-Based Immunotherapy. 31-32	0
7	Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. 2023 , 24, 3151	1
6	The impact of patient factors and tumor characteristics on language neuroplasticity in left hemispheric diffuse gliomas prior to surgical resection.	0
5	Validation of Predictive Analyses for Interim Decisions in Clinical Trials. 2023 ,	0
4	Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. 2023 , 24, e133-e143	0
3	PET Imaging in Gliomas. 2023 , 194-218	0
2	Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.	0
1	Amino Acid PET in Neurooncology. 264859	0